<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Selective progesterone receptor modulators (SPRMs) for uterine fibroids - Murji, A - 2017 | Cochrane Library</title> <meta content="Selective progesterone receptor modulators (SPRMs) for uterine fibroids - Murji, A - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010770.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Selective progesterone receptor modulators (SPRMs) for uterine fibroids - Murji, A - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010770.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010770.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Selective progesterone receptor modulators (SPRMs) for uterine fibroids" name="citation_title"/> <meta content="Ally Murji" name="citation_author"/> <meta content="Mount Sinai Hospital, University of Toronto" name="citation_author_institution"/> <meta content="amurji@mtsinai.on.ca" name="citation_author_email"/> <meta content="Lucy Whitaker" name="citation_author"/> <meta content="Royal Infirmary of Edinburgh" name="citation_author_institution"/> <meta content="Tiffany L Chow" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Mara L Sobel" name="citation_author"/> <meta content="Mount Sinai Hospital, University of Toronto" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010770.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/04/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010770.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010770.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010770.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amenorrhea [drug therapy]; Antineoplastic Agents, Hormonal [*therapeutic use]; Estrenes [*therapeutic use]; Leiomyoma [*drug therapy]; Leuprolide [therapeutic use]; Menstruation [drug effects]; Mifepristone [*therapeutic use]; Norpregnadienes [*therapeutic use]; Oximes [*therapeutic use]; Pelvic Pain [drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone [*antagonists &amp; inhibitors]; Uterine Neoplasms [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010770.pub2&amp;doi=10.1002/14651858.CD010770.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="na56WA6j";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010770\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010770\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010770.pub2",title:"Selective progesterone receptor modulators (SPRMs) for uterine fibroids",firstPublishedDate:"Apr 26, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010770.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010770.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010770.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010770.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010770.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010770.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010770.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010770.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010770.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010770.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8341 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010770.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/appendices#CD010770-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/table_n/CD010770StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/table_n/CD010770StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Selective progesterone receptor modulators (SPRMs) for uterine fibroids</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information#CD010770-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ally Murji</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information#CD010770-cr-0003">Lucy Whitaker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information#CD010770-cr-0004">Tiffany L Chow</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information#CD010770-cr-0005">Mara L Sobel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information/en#CD010770-sec-0141">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 April 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010770.pub2">https://doi.org/10.1002/14651858.CD010770.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010770-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010770-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010770-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010770-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010770-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010770-abs-0001" lang="en"> <section id="CD010770-sec-0001"> <h3 class="title" id="CD010770-sec-0001">Background</h3> <p>Uterine fibroids are smooth muscle tumours arising from the uterus. These tumours, although benign, are commonly associated with abnormal uterine bleeding, bulk symptoms and reproductive dysfunction. The importance of progesterone in fibroid pathogenesis supports selective progesterone receptor modulators (SPRMs) as effective treatment. Both biochemical and clinical evidence suggests that SPRMs may reduce fibroid growth and ameliorate symptoms. SPRMs can cause unique histological changes to the endometrium that are not related to cancer, are not precancerous and have been found to be benign and reversible. This review summarises randomised trials conducted to evaluate the effectiveness of SPRMs as a class of medication for treatment of individuals with fibroids. </p> </section> <section id="CD010770-sec-0002"> <h3 class="title" id="CD010770-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of SPRMs for treatment of premenopausal women with uterine fibroids. </p> </section> <section id="CD010770-sec-0003"> <h3 class="title" id="CD010770-sec-0003">Search methods</h3> <p>We searched the Specialised Register of the Cochrane Gynaecology and Fertility Group, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and clinical trials registries from database inception to May 2016. We handsearched the reference lists of relevant articles and contacted experts in the field to request additional data. </p> </section> <section id="CD010770-sec-0004"> <h3 class="title" id="CD010770-sec-0004">Selection criteria</h3> <p>Included studies were randomised controlled trials (RCTs) of premenopausal women with fibroids who were treated for at least three months with a SPRM. </p> </section> <section id="CD010770-sec-0005"> <h3 class="title" id="CD010770-sec-0005">Data collection and analysis</h3> <p>Two review authors independently reviewed all eligible studies identified by the search. We extracted data and assessed risk of bias independently using standard forms. We analysed data using mean differences (MDs) or standardised mean differences (SMDs) for continuous data and odds ratios (ORs) for dichotomous data. We performed meta‐analyses using the random‐effects model. Our primary outcome was change in fibroid‐related symptoms. </p> </section> <section id="CD010770-sec-0006"> <h3 class="title" id="CD010770-sec-0006">Main results</h3> <p>We included in the review 14 RCTs with a total of 1215 study participants. We could not extract complete data from three studies. We included in the meta‐analysis 11 studies involving 1021 study participants: 685 received SPRMs and 336 were given a control intervention (placebo or leuprolide). Investigators evaluated three SPRMs: mifepristone (five studies), ulipristal acetate (four studies) and asoprisnil (two studies). The primary outcome was change in fibroid‐related symptoms (symptom severity, health‐related quality of life, abnormal uterine bleeding, pelvic pain). Adverse event reporting in the included studies was limited to SPRM‐associated endometrial changes. More than half (8/14) of these studies were at low risk of bias in all domains. The most common limitation of the other studies was poor reporting of methods. The main limitation for the overall quality of evidence was potential publication bias. </p> <p><i><b>SPRM versus placebo</b> </i> </p> <p>SPRM treatment resulted in improvements in fibroid symptom severity (MD ‐20.04 points, 95% confidence interval (CI) ‐26.63 to ‐13.46; four RCTs, 171 women, I<sup>2</sup> = 0%; moderate‐quality evidence) and health‐related quality of life (MD 22.52 points, 95% CI 12.87 to 32.17; four RCTs, 200 women, I<sup>2</sup> = 63%; moderate‐quality evidence) on the Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL, scale 0 to 100). Women treated with an SPRM showed reduced menstrual blood loss on patient‐reported bleeding scales, although this effect was small (SMD ‐1.11, 95% CI ‐1.38 to ‐0.83; three RCTs, 310 women, I<sup>2</sup> = 0%; moderate‐quality evidence), along with higher rates of amenorrhoea (29 per 1000 in the placebo group vs 237 to 961 per 1000 in the SPRM group; OR 82.50, 95% CI 37.01 to 183.90; seven RCTs, 590 women, I<sup>2</sup> = 0%; moderate‐quality evidence), compared with those given placebo. We could draw no conclusions regarding changes in pelvic pain owing to variability in the estimates. With respect to adverse effects, SPRM‐associated endometrial changes were more common after SPRM therapy than after placebo (OR 15.12, 95% CI 6.45 to 35.47; five RCTs, 405 women, I<sup>2</sup> = 0%; low‐quality evidence). </p> <p><i><b>SPRM versus leuprolide acetate</b> </i> </p> <p>In comparing SPRM versus other treatments, two RCTs evaluated SPRM versus leuprolide acetate. One RCT reported primary outcomes. No evidence suggested a difference between SPRM and leuprolide groups for improvement in quality of life, as measured by UFS‐QoL fibroid symptom severity scores (MD ‐3.70 points, 95% CI ‐9.85 to 2.45; one RCT, 281 women; moderate‐quality evidence) and health‐related quality of life scores (MD 1.06 points, 95% CI ‐5.73 to 7.85; one RCT, 281 women; moderate‐quality evidence). It was unclear whether results showed a difference between SPRM and leuprolide groups for reduction in menstrual blood loss based on the pictorial blood loss assessment chart (PBAC), as confidence intervals were wide (MD 6 points, 95% CI ‐40.95 to 50.95; one RCT, 281 women; low‐quality evidence), or for rates of amenorrhoea (804 per 1000 in the placebo group vs 732 to 933 per 1000 in the SPRM group; OR 1.14, 95% CI 0.60 to 2.16; one RCT, 280 women; moderate‐quality evidence). No evidence revealed differences between groups in pelvic pain scores based on the McGill Pain Questionnaire (scale 0 to 45) (MD ‐0.01 points, 95% CI ‐2.14 to 2.12; 281 women; moderate‐quality evidence). With respect to adverse effects, SPRM‐associated endometrial changes were more common after SPRM therapy than after leuprolide treatment (OR 10.45, 95% CI 5.38 to 20.33; 301 women; moderate‐quality evidence). </p> </section> <section id="CD010770-sec-0007"> <h3 class="title" id="CD010770-sec-0007">Authors' conclusions</h3> <p>Short‐term use of SPRMs resulted in improved quality of life, reduced menstrual bleeding and higher rates of amenorrhoea than were seen with placebo. Thus, SPRMs may provide effective treatment for women with symptomatic fibroids. Evidence derived from one RCT showed no difference between leuprolide acetate and SPRM with respect to improved quality of life and bleeding symptoms. Evidence was insufficient to show whether effectiveness was different between SPRMs and leuprolide. Investigators more frequently observed SPRM‐associated endometrial changes in women treated with SPRMs than in those treated with placebo or leuprolide acetate. As noted above, SPRM‐associated endometrial changes are benign, are not related to cancer and are not precancerous. Reporting bias may impact the conclusion of this meta‐analysis. Well‐designed RCTs comparing SPRMs versus other treatments are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010770-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010770-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010770-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010770-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010770-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010770-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010770-abs-0004" lang="en"> <h3>Drugs to treat fibroids</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence on effectiveness and safety of a new class of medications called selective progesterone receptor modulators (SPRMs) for treating premenopausal women with uterine fibroids. </p> <p><b>Background</b> </p> <p>Fibroids (non‐cancerous masses within the muscle layer of the womb) are a common condition. Fibroids can negatively impact a woman's health by causing heavy periods, creating symptoms related to their size (such as pressing on the bladder or rectum) and/or making it difficult to conceive. </p> <p>A new class of medication called SPRMs has shown promise for treatment of women with fibroids. The class of SPRMs includes various drugs such as mifepristone, ulipristal acetate and asoprisnil. SPRMs can cause benign changes to the endometrium that are not related to cancer and are not precancerous. </p> <p><b>Search date</b> </p> <p>We searched the literature up to May 2016.</p> <p><b>Study characteristics</b> </p> <p>Review authors included 14 randomised controlled trials (RCTs) (1215 women) but could not obtain data from three studies. In addition, several completed registered trials had not yet reported findings. This review evaluated results of 11 RCTs that included 1021 women with fibroids. Investigators treated women with mifepristone (five studies), ulipristal acetate (four studies) or asoprisnil (two studies) and compared SPRMs with either placebo or leuprolide acetate. More than half of these studies were at low risk of bias in all domains. The most common limitation of the other studies was poor reporting of methods. </p> <p><b>Key results</b> </p> <p>The main outcomes studied were changes in symptoms (fibroid‐related symptom severity, quality of life, menstrual bleeding, pelvic pain). When compared with placebo (identical "dummy" tablet that contains no active medication), SPRMs improved fibroid‐related symptoms (by an average effect of 20 points on a 100‐point scale), improved women's quality of life (by an average effect of 22 points on a 100‐point scale) and resulted in a small decrease in menstrual bleeding. Between 24% and 96% of women treated with SPRMs had no period at all (compared with 3% taking placebo). Review authors could draw no conclusions about changes in pelvic pain, as this was not consistently evaluated. Two studies compared SPRMs versus a gonadotropin‐releasing hormone agonist (leuprolide) and found that both drugs (SPRMs and leuprolide) were effective in improving symptoms related to fibroids (improving quality of life, reducing menstrual bleeding, causing cessation of periods, decreasing pelvic pain). However, we are not sure if researchers noted a difference in effectiveness between SPRMs and leuprolide. </p> <p>Women treated with SPRMs were more likely to develop changes to the lining of the womb (endometrium) than women treated with placebo or leuprolide. These changes are benign and reversible once SPRMs are discontinued. </p> <p>In summary, the studies included in this review show that SPRMs improve fibroid‐related symptoms, quality of life and menstrual bleeding. However, we need larger, well‐designed studies comparing SPRMs against other treatments currently available for the management of fibroids. </p> <p><b>Quality of the evidence</b> </p> <p>In comparisons with placebo, moderate‐quality evidence showed improvements in quality of life, reduction in menstrual bleeding and cessation of periods with SPRMs. Low‐quality evidence suggested a higher rate of changes to the endometrium with SPRM treatment than with placebo. Comparisons with leuprolide were based on moderate‐quality evidence for changes in quality of life, cessation of periods, pelvic pain and endometrial changes. The main limitation in the overall quality of evidence was potential publication bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010770-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010770-sec-0104"></div> <h3 class="title" id="CD010770-sec-0105">Implications for practice</h3> <section id="CD010770-sec-0105"> <p>In comparison with placebo, evidence suggests that SPRMs may improve fibroid‐related symptoms and quality of life, while inducing amenorrhoea, controlling heavy menstrual bleeding and producing fibroid and uterine shrinkage. A three‐month treatment course with this class of drugs does not result in premalignant or malignant transformation of the endometrium. However, SPRM‐associated endometrial changes are frequently observed with administration of all SPRMs, and histopathologists must be apprised of these benign endometrial features. Moderate‐quality data based on one study show that differences between SPRM and leuprolide acetate (in the class of gonadotropin‐releasing hormone agonists) in treating fibroid‐related symptoms are probably few if they are noted at all. Both classes of medications are effective in improving quality of life and controlling menstrual bleeding. For secondary outcomes, limited evidence shows that leuprolide causes greater shrinkage of fibroid and uterine volume. However, although less fibroid shrinkage was reported after UPA administration, overall reduction in this group occurred as a change of 36 percentage points, which is clinically meaningful.For example, a reduction in fibroid size of this magnitude may facilitate a laparoscopic rather than an abdominal approach. </p> <p>Given that both SPRM and leuprolide improve quality of life and that there is probably little or no difference between them, the choice of medication should be made based on patient/clinician preferences, taking into account issues such as route of administration, costs, presence of other disease processes and side‐effect profiles. </p> <p>Overall, limited evidence is available on the use of SPRMs over other medical treatment options for fibroids. </p> </section> <h3 class="title" id="CD010770-sec-0106">Implications for research</h3> <section id="CD010770-sec-0106"> <p>Well‐designed RCTs are needed to compare SPRMs versus other treatment options for fibroids. Study cohorts should reflect patient demographics, particularly with respect to ethnicity. Multiple potentially useful SPRMs are available, and evidence of efficacy compared with placebo, other medical treatments or surgical interventions is required. Outcome measures must assess quality of life, treatment adherence and patient satisfaction, as well as objective and standardised measures of uterine bleeding, fibroid and uterine size. Investigators should use consistent core reporting outcomes (<a href="./references#CD010770-bbs2-0060" title="KhanK . The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health. BJOG2014; Vol. 121, issue 10:1181‐2. [PUBMED: 24889142] ">Khan 2014</a>) to facilitate meaningful comparisons. </p> <p>Publication bias impacts meta‐analyses and potentially influenced this review. As such, transparency in clinical research should continue to be advocated at all levels. Cost‐effectiveness analysis should be considered if SPRMs are to be used as longer‐term medical treatment options. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010770-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010770-sec-0022"></div> <div class="table" id="CD010770-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">SPRM versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>SPRM vs placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with uterine fibroids<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> SPRM<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SPRM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in symptom severity score measured with Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL): scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in symptom severity score (QoL) in the intervention group was 20.04 points lower (26.63 lower to 13.46 lower), indicating improvement in symptom severity with SPRM treatment for 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in health‐related quality of life score measured with UFS‐QoL: scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in health‐related quality of life score in the intervention group was 22.52 points higher (12.87 higher to 32.17 higher), indicating improvement in quality of life with SPRM treatment for 3 to 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 RCT (Fiscella 2006) reported outcomes at 6 months. Remaining studies had a 3‐month follow‐up period </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> change in menstrual blood loss </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in menstrual blood loss in the intervention group was 1.11 points lower (1.38 lower to 0.83 lower), indicating a decrease in menstrual blood loss with SPRM treatment for 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured by PBAC score or similar menstrual pictorial score. PBAC score ≥ 100 correlates with menorrhagia, which is defined as &gt; 80 mL menstrual blood loss </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> amenorrhoea </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>477 per 1000<br/> (237 to 961) with 3 to 6 months of SPRM treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 82.50<br/> (37.10 to 183.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 RCT (Fiscella 2006) reported outcomes at 6 months. Remaining studies had a 3‐month follow‐up period </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pelvic pain</b> (measured subjectively) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No conclusions could be drawn owing to variability in estimates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>629</p> <p>(7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> SPRM‐associated endometrial changes </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000<br/> (176 to 697) with 3 months of SPRM treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 15.12<br/> (6.45 to 35.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>Risk in the intervention group</b> (and its 95% confidence interval) is based on mean risk in the comparison group and <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as publication bias suspected because no small negative studies included. Also, many studies were conducted and not published </p> <p><sup>b</sup>Downgraded one level because of serious issues with indirectness of evidence when criteria for evaluating endometrial specimens differed between studies </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010770-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">SPRM versus leuprolide acetate for uterine fibroids</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SPRM versus leuprolide acetate for uterine fibroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> uterine fibroids<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> SPRM<br/> <b>Comparison:</b> leuprolide acetate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with leuprolide acetate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SPRM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in symptom severity score measured with Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL): scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in symptom severity score (QoL) in the SPRM group was 3.7 points lower<br/> (9.85 lower to 2.45 higher) compared with the leuprolide group at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in health‐related quality of life score measured with UFS‐QoL: scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in health‐related quality of life score in the SPRM group was 1.06 points higher<br/> (5.73 lower to 7.85 higher) compared with the leuprolide group at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> change in menstrual blood loss (measured using PBAC score) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in menstrual blood loss in the SPRM group was 6 points higher<br/> (40.95 lower to 52.95 higher) compared with the leuprolide group at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score ≥ 100 correlates with menorrhagia, which is defined as &gt; 80 mL menstrual blood loss </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> amenorrhoea </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>804 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>828 per 1000<br/> (732 to 933) at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.14<br/> (0.60 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pelvic pain</b> (measured using McGill Pain Questionnaire: range 0 to 45) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean change in pelvic pain in the SPRM group was 0.01 points lower (2.14 lower to 2.12 higher) than in the leuprolide group at 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> SPRM‐associated endometrial changes </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>585 per 1000<br/> (340 to 1000) after 3 months of treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 10.45<br/> (5.38 to 20.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>Risk in the intervention group</b> (and its 95% confidence interval) is based on mean risk in the comparison group and <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as publication bias strongly suspected </p> <p><sup>b</sup>Downgraded one level owing to serious issue with imprecision as point estimate has very wide confidence interval </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010770-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010770-sec-0023"></div> <section id="CD010770-sec-0024"> <h3 class="title" id="CD010770-sec-0024">Description of the condition</h3> <p>Uterine fibroids are common smooth muscle tumours arising from the uterus. They are also known as leiomyomata or myomas. The prevalence of these tumours depends on the population’s ethnicity and the method of detection. More than 80% of black women and nearly 70% of white women will develop fibroids before the age of 50 years (<a href="./references#CD010770-bbs2-0045" title="BairdDD , DunsonDB , HillMC , CousinsD , SchectmanJM . High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics and Gynecology2003;188(1):100‐7. [PUBMED: 12548202] ">Baird 2003</a>). These tumours, although benign, can cause significant distortion of the uterus and result in symptoms in up to 50% of women (<a href="./references#CD010770-bbs2-0045" title="BairdDD , DunsonDB , HillMC , CousinsD , SchectmanJM . High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics and Gynecology2003;188(1):100‐7. [PUBMED: 12548202] ">Baird 2003</a>). Fibroids are frequently associated with abnormal uterine bleeding, bulk symptoms (pelvic pressure, urinary dysfunction, constipation, pain) and reproductive dysfunction (subfertility, miscarriage, pregnancy complications) (<a href="./references#CD010770-bbs2-0069" title="StovallDW . Clinical symptomatology of uterine leiomyomas. Clinical Obstetrics and Gynecology2001;44(2):364‐71. [PUBMED: 11344999] ">Stovall 2001</a>).  </p> <p>In the United States alone, the direct cost of treatment for women with fibroids is estimated to be over four billion dollars annually (<a href="./references#CD010770-bbs2-0049" title="CardozoER , ClarkAD , BanksNK , HenneMB , StegmannBJ , SegarsJH . The estimated annual cost of uterine leiomyomata in the United States. American Journal of Obstetrics and Gynecology2012;206(3):211.e1‐9. [PUBMED: 22244472] ">Cardozo 2012</a>). Fibroid‐related symptoms can be treated with surgery (hysterectomy, myomectomy, endometrial ablation, myolysis), minimally invasive procedures (uterine artery embolisation, magnetic resonance‐guided focused ultrasound) or medical therapies (<a href="./references#CD010770-bbs2-0074" title="WallachEE , VlahosNF . Uterine myomas: an overview of development, clinical features, and management. Obstetrics and Gynecology2004;104(2):393‐406. [PUBMED: 15292018] ">Wallach 2004</a>). Despite these treatment options, hysterectomy is the second most frequently performed surgical procedure in the United States, with fibroids the most common indication (<a href="./references#CD010770-bbs2-0062" title="MerrillRM . Hysterectomy surveillance in the United States, 1997 through 2005. Medical Science Monitor2008;14(1):CR24‐31. [PUBMED: 18160941] ">Merrill 2008</a>); this has contributed to significant surgical morbidity and escalating healthcare costs. Thus, focus on more conservative options is needed.   </p> </section> <section id="CD010770-sec-0025"> <h3 class="title" id="CD010770-sec-0025">Description of the intervention</h3> <p>Currently, no pharmacological agents have received global approval specifically for long‐term treatment of individuals with uterine fibroids. The mainstay of medical management has comprised use of gonadotropin‐releasing hormone analogues (GnRHa) for preoperative optimisation seen as decreased blood loss, corrected anaemia and reduced fibroid volume (<a href="./references#CD010770-bbs2-0066" title="SabryM , Al‐HendyA . Medical treatment of uterine leiomyoma. Reproductive Sciences2012;19(4):339‐53. [PUBMED: 22378865] ">Sabry 2012</a>).  Leuprolide acetate is one of the most frequently used GnRHa treatments for fibroids and is approved in the United States and Europe for this indication. Challenges associated with GnRHa therapy include decreased bone mineral density, development of vasomotor symptoms and an initial oestrogen flare that may exacerbate symptoms. Although medical therapies such as combined hormonal contraceptives, progestins, progestin‐releasing intrauterine systems and danazol may be used to decrease menstrual blood flow, their specific effects on fibroids and bulk symptoms are limited, and they often cause side effects that lead to discontinuation (<a href="./references#CD010770-bbs2-0059" title="KeLQ , YangK , LiJ , LiCM . Danazol for uterine fibroids. Cochrane Database of Systematic Reviews2011, Issue 9. [DOI: 10.1002/14651858.CD007692.pub2] ">Ke 2009</a>; <a href="./references#CD010770-bbs2-0067" title="SangkomkamhangUS , LumbiganonP , LaopaiboonM , MolBW . Progestogens or progestogen‐releasing intrauterine systems for uterine fibroids. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD008994.pub2] ">Sangkomkamhang 2013</a>; <a href="./references#CD010770-bbs2-0072" title="VanVoorhisB . A 41‐year‐old woman with menorrhagia, anemia, and fibroids: review of treatment of uterine fibroids. JAMA2009;301(1):82‐93. [PUBMED: 19050179] ">Van Voorhis 2009</a>). </p> <p>Traditionally, oestrogen has been considered the most important hormone for stimulating fibroid growth. Recently, progesterone was found to be essential for the maintenance and growth of fibroids (<a href="./references#CD010770-bbs2-0048" title="BulunSE . Uterine fibroids. New England Journal of Medicine2013;369(14):1344‐55. [PUBMED: 24088094] ">Bulun 2013</a>). For this reason, selective progesterone receptor modulators (SPRMs) have shown promise for the treatment of women with uterine fibroids (<a href="./references#CD010770-bbs2-0050" title="ChwaliszK , PerezMC , DemannoD , WinkelC , SchubertG , ElgerW . Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews2005;26(3):423‐38. [PUBMED: 15857972] ">Chwalisz 2005</a>). These molecules bind to the progesterone receptor and show varying levels of antagonistic activity. SPRMs were first discovered in 1980, and mifepristone, a powerful progesterone antagonist, was the pioneer drug. It has been used mainly for pregnancy termination but has also been evaluated as a therapeutic agent for fibroids. Meta‐analysis of three randomised trials showed that mifepristone is effective in reducing bleeding symptoms and improving fibroid‐related quality of life, with no effect on fibroid volume (<a href="./references#CD010770-bbs2-0071" title="TristanM , OrozcoLJ , SteedA , Ramirez‐MoreraA , StoneP . Mifepristone for uterine fibroids. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD007687.pub2] ">Tristan 2012</a>).   </p> <p>Other SPRMs were subsequently developed, each with different affinity for the progesterone receptor and showing varying degrees of antagonistic activity. The clinical activity of each SPRM class member reflects the subtlety of its spectrum of agonist and antagonist activity, along with tissue‐specific expression of progesterone receptor (PR) subtypes. </p> </section> <section id="CD010770-sec-0026"> <h3 class="title" id="CD010770-sec-0026">How the intervention might work</h3> <p>The ‘progesterone hypothesis’ suggests that progesterone acts as a key hormone in the development of fibroids by increasing mitotic rates and reducing apoptosis of fibroid smooth muscle cells (<a href="./references#CD010770-bbs2-0048" title="BulunSE . Uterine fibroids. New England Journal of Medicine2013;369(14):1344‐55. [PUBMED: 24088094] ">Bulun 2013</a>). Data also suggest that signalling occurs between oestrogen and progesterone receptors, whereby oestrogen induces increased expression of the progesterone receptor in fibroid cells (<a href="./references#CD010770-bbs2-0057" title="IshikawaH , IshiK , SernaVA , KakazuR , BulunSE , KuritaT . Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology2010;151(6):2433‐42. [PUBMED: 20375184] ">Ishikawa 2010</a>). The importance of progesterone in fibroid pathogenesis supports SPRMs as effective treatment for women with fibroids. Fibroid cells cultured with SPRMs demonstrate inhibited proliferation and increased apoptosis, without affecting normal myometrium (<a href="./references#CD010770-bbs2-0046" title="BouchardP , Chabbert‐BuffetN , FauserBC . Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertility and Sterility2011;96(5):1175‐89. [PUBMED: 21944187] ">Bouchard 2011</a>). SPRMs can also downregulate the number of growth factors while reducing collagen synthesis in cultured fibroid cells (<a href="./references#CD010770-bbs2-0046" title="BouchardP , Chabbert‐BuffetN , FauserBC . Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertility and Sterility2011;96(5):1175‐89. [PUBMED: 21944187] ">Bouchard 2011</a>). SPRMs act upon the uterine endometrium to provide relief of bleeding symptoms in women with fibroids (<a href="./references#CD010770-bbs2-0073" title="WagenfeldA , SaundersPT , WhitakerL , CritchleyHO . Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opinion on Therapeutic Targets2016;20(9):1‐10. [PUBMED: 27138351] ">Wagenfeld 2016</a>). SPRMs are known to cause unique changes to the endometrium. Histological endometrial changes have been labelled as progesterone receptor modulator‐associated endometrial changes (PAECs) on the basis of international consensus (<a href="./references#CD010770-bbs2-0064" title="MutterGL , BergeronC , DeligdischL , FerenczyA , GlantM , MerinoM , et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology2008;21(5):591‐8. [PUBMED: 18246050] ">Mutter 2008</a>). These changes are benign and reversible. </p> <p>SPRMs may be used to treat women with fibroids in several clinical scenarios. Currently, the only SPRM approved for medical management of fibroids is ulipristal acetate (Esmya, Gedeon‐Richter, Europe, February 2012; Fibristal, Watson Laboratories Inc, Canada, July 2013). This drug was approved to treat bleeding symptoms while decreasing fibroid size for up to three months before surgery. Recently, it was approved in Europe and Canada for ongoing intermittent use. Long‐term use of SPRMs for fibroid‐related symptoms may decrease the need for surgical intervention and associated morbidity and costs. Long‐term medical therapy may be particularly beneficial for bridging perimenopausal women until menopause, when fibroids would then spontaneously decrease. Although pregnancy is contraindicated with SPRMs, evidence shows that the decrease in fibroid size is sustained after the medication has been discontinued (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>). This may cause fibroid‐related subfertility, for which medical management may reduce fibroid volume and facilitate pregnancy after discontinuation of SPRM treatment. </p> </section> <section id="CD010770-sec-0027"> <h3 class="title" id="CD010770-sec-0027">Why it is important to do this review</h3> <p>Despite the prevalence of uterine fibroids, only a few high‐quality studies have examined the effectiveness of medical therapies. With increasing demand for less invasive fibroid therapies, the benefits and risks of medical treatments must be critically evaluated. Furthermore, women are delaying childbearing, hence fertility‐sparing therapeutic options are needed. Biochemical and clinical evidence shows that SPRMs may decrease fibroid growth and ameliorate symptoms (<a href="./references#CD010770-bbs2-0050" title="ChwaliszK , PerezMC , DemannoD , WinkelC , SchubertG , ElgerW . Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews2005;26(3):423‐38. [PUBMED: 15857972] ">Chwalisz 2005</a>). Although a Cochrane review on mifepristone has been completed (<a href="./references#CD010770-bbs2-0071" title="TristanM , OrozcoLJ , SteedA , Ramirez‐MoreraA , StoneP . Mifepristone for uterine fibroids. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD007687.pub2] ">Tristan 2012</a>), the newer SPRMs require systematic evaluation of their benefits and harms.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010770-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010770-sec-0028"></div> <p>To evaluate the effectiveness and safety of selective progesterone receptor modulators (SPRMs) for treatment of premenopausal women with uterine fibroids.  </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010770-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010770-sec-0029"></div> <section id="CD010770-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010770-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included data from all published and unpublished randomised controlled trials (RCTs). For cross‐over studies, we included for meta‐analysis only data from the first phase of the trial.  </p> </section> <section id="CD010770-sec-0032"> <h4 class="title">Types of participants</h4> <p>Premenopausal women with uterine fibroids, with or without symptoms. The presence of fibroids was confirmed surgically (laparoscopy, laparotomy or hysteroscopy) or through at least one of the following imaging modalities: ultrasonography, computed tomography or magnetic resonance imaging (MRI).  </p> </section> <section id="CD010770-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Treatment with any SPRM for at least three months versus:</p> <p> <ul id="CD010770-list-0001"> <li> <p>placebo;</p> </li> <li> <p>no treatment;</p> </li> <li> <p>another medical therapy (another SPRM, a GnRHa or another class of medication);</p> </li> <li> <p>surgery (myomectomy or hysterectomy); or</p> </li> <li> <p>uterine artery embolisation (UAE).</p> </li> </ul> </p> <p>Commercially available SPRMs included, but were not limited to, mifepristone, asoprisnil, telapristone acetate and ulipristal acetate. Additional interventions were permitted as long as they were uniformly used in all study arms. Leuprolide acetate is a GnRHa that is commonly used to treat fibroids. We searched for comparisons of SPRM versus leuprolide acetate or other medications in the GnRHa class. </p> </section> <section id="CD010770-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010770-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010770-list-0002"> <li> <p>Change in fibroid‐related symptoms</p> <ul id="CD010770-list-0003"> <li> <p>Quality of life assessed through standardised and validated measures. Examples of scales that measured health‐related quality of life for women with uterine fibroids (<a href="./references#CD010770-bbs2-0076" title="WilliamsVS , JonesG , MauskopfJ , SpaldingJ , DuChaneJ . Uterine fibroids: a review of health‐related quality of life assessment. Journal of Womens Health2006;15(7):818‐29. [PUBMED: 16999637] ">Williams 2006</a>) included but were not limited to Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL) (<a href="./references#CD010770-bbs2-0068" title="SpiesJB , CoyneK , Guaou GuaouN , BoyleD , Skyrnarz‐MurphyK , GonzalvesSM . The UFS‐QOL, a new disease‐specific symptom and health‐related quality of life questionnaire for leiomyomata. Obstetrics and Gynecology2002;99(2):290‐300. [PUBMED: 11814511] ">Spies 2002</a>), EuroQoL (<a href="./references#CD010770-bbs2-0047" title="BrooksR . EuroQol: the current state of play. Health Policy1996;37(1):53‐72. [PUBMED: 10158943] ">Brooks 1996</a>) and Short Form‐36 (SF‐36) (<a href="./references#CD010770-bbs2-0075" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473‐83. [PUBMED: 1593914] ">Ware 1992</a>) </p> </li> <li> <p>Abnormal uterine bleeding measured objectively (e.g. haemoglobin levels, haematocrit, ferritin levels, alkaline haematin technique) or subjectively (e.g. pictorIal blood loss assessment) </p> </li> <li> <p>Pain and pelvic pressure measured subjectively (e.g. visual analogue scales, Likert scales) </p> </li> </ul> </li> </ul> </p> </section> <section id="CD010770-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010770-list-0004"> <li> <p>Change in fibroid or uterine size, or both, as measured by ultrasonography or MRI</p> </li> <li> <p>SPRM‐related effects including, but not limited to, SPRM‐associated endometrial changes (<a href="./references#CD010770-bbs2-0064" title="MutterGL , BergeronC , DeligdischL , FerenczyA , GlantM , MerinoM , et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology2008;21(5):591‐8. [PUBMED: 18246050] ">Mutter 2008</a>), endometrial hyperplasia, endometrial carcinoma, abnormal liver enzymes and prolactin levels, osteoporosis, breast discomfort, hot flushes, headache and nausea </p> </li> </ul> </p> </section> </section> </section> <section id="CD010770-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs of SPRMs used for treatment of uterine fibroids. We applied no language restrictions. We developed and executed the search strategy in consultation with the Cochrane Gynaecology and Fertility Group Information Specialist and a Mount Sinai Hospital librarian. </p> <section id="CD010770-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from inception until 15 May 2016.</p> <p> <ul id="CD010770-list-0005"> <li> <p>Cochrane Gynaecology and Fertility Group Specialised Register (<a href="./appendices#CD010770-sec-0110">Appendix 1</a>). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (<a href="./appendices#CD010770-sec-0111">Appendix 2</a>). </p> </li> <li> <p>MEDLINE (<a href="./appendices#CD010770-sec-0112">Appendix 3</a>). </p> </li> <li> <p>Embase (<a href="./appendices#CD010770-sec-0113">Appendix 4</a>). </p> </li> <li> <p>PsycINFO (<a href="./appendices#CD010770-sec-0114">Appendix 5</a>). </p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL)0 (<a href="./appendices#CD010770-sec-0115">Appendix 6</a>). </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE) (<a href="./appendices#CD010770-sec-0116">Appendix 7</a>). </p> </li> <li> <p>Other.</p> </li> </ul> <ul class="plain" id="CD010770-list-0006"> <li> <ul id="CD010770-list-0007"> <li> <p>Trial registers for ongoing and registered trials: www.clinicaltrials.gov.</p> </li> <li> <p>Web of Knowledge: http://wokinfo.com/.</p> </li> <li> <p>Clinical study results for clinical trials of marketed pharmaceuticals: <a href="http://www.clinicalstudyresults.org" target="_blank">www.clinicalstudyresults.org.</a> </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform: <a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch.</a> </p> </li> <li> <p>OpenGrey for unpublished literature from Europe: <a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu.</a> </p> </li> <li> <p>Latin American Caribbean Health Sciences Literature (LILACS) for Portuguese and Spanish trials. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD010770-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We handsearched appropriate journals recommended by the Gynaecology and Fertility Group that were not captured in the above databases. We also handsearched reference lists of relevant articles and contacted experts in the field to obtain additional data. </p> </section> </section> <section id="CD010770-sec-0040"> <h3 class="title" id="CD010770-sec-0040">Data collection and analysis</h3> <p>We performed statistical analysis according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010770-bbs2-0055" title="HigginsJPT , GreenS , editors. Cochrane handbook for systematic reviews of interventions. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). We used Review Manager 5.3 (<a href="./references#CD010770-bbs2-0065" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) software for the analysis.  </p> <section id="CD010770-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently completed the initial title and abstract screening. We retrieved full texts when studies met the following criteria: used an SPRM as an intervention for treatment of uterine fibroids, and had a prospective design. If we had any doubts based on these screening criteria, we retrieved the full text. We excluded studies if full‐text articles did not mention randomisation. We resolved disagreements during the screening process by consulting a third review author. We documented the selection process in a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) flow diagram (<a href="#CD010770-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010770-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010770-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010770-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from all eligible studies to be included in the review. We extracted data using forms that we had pilot‐tested. These forms included specifics of study characteristics and outcomes data. When data from a trial had been published more than once, review authors extracted data that were additional and were not repeated. We contacted trial authors for clarification when required. We resolved disagreements between review authors by consensus after involving an additional review author. </p> </section> <section id="CD010770-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed bias for included studies using the Cochrane risk of bias tool (<a href="http://www.cochrane-handbook.org" target="_blank">www.cochrane‐handbook.org</a>). We assessed the following elements: selection bias (random sequence generation, allocation concealment); performance bias (blinding of participants and personnel); detection bias (blinding of outcome assessors); attrition bias (incomplete outcome data); reporting bias (selective reporting); and other biases. We paid special attention to within‐trial selective reporting when study authors failed to report obvious outcomes or reported them with insufficient detail. We compared studies against published protocols to determine whether planned outcome measures were indeed reported.   </p> </section> <section id="CD010770-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the various comparisons separately using RevMan 5.3. We reported dichotomous data as odds ratios (ORs) with 95% confidence intervals (CIs). We reported continuous data as mean differences (MDs) with 95% CIs. When outcomes were reported as continuous data on different scales, we reported standardised mean differences (SMDs) and 95% CIs.  </p> <p>We interpreted the SMD using the following rule‐of‐thumb guide: 0.2 represents a small effect, 0.5 a moderate effect and 0.8 a large effect (<a href="./references#CD010770-bbs2-0051" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd Edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1988. ">Cohen 1988</a>). </p> </section> <section id="CD010770-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We performed the primary analysis per woman randomised.</p> <p>We prepared additional tables to briefly summarise data that did not allow valid analysis (e.g. 'per cycle' data) and did not meta‐analyse these data. This applied to "change in fibroid size data", which we analysed on the basis of number of fibroids tracked ‐ not number of participants (i.e. some participants contributed more fibroids to the analysis than others). </p> <p>We included only first‐phase data from cross‐over trials.</p> </section> <section id="CD010770-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted primary authors electronically to request missing data and clarification of any issues that arose. We analysed data on the basis of intention‐to‐treat analysis. When all randomised participants were not included in the analysis, we calculated and separately reported the percentage of participants lost to follow‐up. In these cases, we imputed values only for primary outcomes. For other outcomes, we analysed only available data. </p> <p>When data were reported in a form unsuitable for analysis (e.g. did not report standard deviations or reported medians rather than means), we obtained statistical advice and imputed the data (see <a href="./appendices#CD010770-sec-0121">Appendix 12</a>). </p> </section> <section id="CD010770-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated included trials to determine whether studied participants, interventions and outcomes were similar enough that we could meta‐analyse them. If we determined that trials could be meta‐analysed to yield clinically relevant results, we assessed these trials for statistical heterogeneity. We performed tests for heterogeneity across studies by using the Q statistic and the I<sup>2</sup> statistic. We used the following criteria for heterogeneity: I<sup>2</sup> &lt; 25% showed low, 25% to 50% moderate and &gt; 50% high heterogeneity (<a href="./references#CD010770-bbs2-0055" title="HigginsJPT , GreenS , editors. Cochrane handbook for systematic reviews of interventions. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). When we found high heterogeneity across any of these criteria, we conducted subgroup and sensitivity analyses. </p> </section> <section id="CD010770-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We aimed to minimise reporting bias by completing a comprehensive search for eligible studies while staying conscious of data duplication. If we found a sufficient number of trials for inclusion (&gt; 10), we used a funnel plot to assess for publication bias (under‐reporting of small negative studies). </p> </section> <section id="CD010770-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We pooled data for clinically similar studies using a random‐effects model for the meta‐analysis. When studies could not be pooled, we described outcomes in narrative form. We analysed different comparisons separately. </p> <p> <ul id="CD010770-list-0008"> <li> <p>All SPRMs versus placebo or no treatment.</p> </li> <li> <p>All SPRMs versus alternative active therapy, stratified by alternatives.</p> <ul id="CD010770-list-0009"> <li> <p>SPRMs versus medical therapy (stratified by class of medical therapy).</p> </li> <li> <p>SPRMs versus surgical management (stratified by type of surgical management).</p> </li> <li> <p>SPRMs versus UAE.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD010770-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses if sufficient data were available (i.e. more than five studies). </p> <p> <ul id="CD010770-list-0010"> <li> <p>Individual types of SPRMs versus placebo, no treatment or each alternative active therapy. </p> </li> <li> <p>Duration of therapy (&lt; 6 months, 6 to 12 months, &gt; 12 months).</p> </li> <li> <p>SPRM dose (low, medium, high).</p> </li> <li> <p>Fibroid location (submucous, intramural, subserosal).</p> </li> </ul> </p> <p>When high heterogeneity was present, we planned to explore possible explanations including individual study risk of bias, participant population (age, ethnicity, types and sizes of fibroids), dose of SPRM, duration of treatment and follow‐up.   </p> </section> <section id="CD010770-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses for primary outcomes when data were sufficient (more than five studies) to determine whether conclusions were robust to arbitrary decisions made regarding eligibility and analysis. These planned analyses included consideration of whether review conclusions would have differed if: </p> <p> <ul id="CD010770-list-0011"> <li> <p>eligibility had been restricted to studies without high risk of bias;</p> </li> <li> <p>a fixed‐effect model had been adopted;</p> </li> <li> <p>alternative imputation strategies had been implemented; or</p> </li> <li> <p>the summary effect measure had been risk ratio rather than odds ratio.</p> </li> </ul> </p> <section id="CD010770-sec-0052"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We prepared a 'Summary of findings' table using GRADEpro (<a href="./references#CD010770-bbs2-0053" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed before November 2016. Hamilton, ON: GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>) and Cochrane methods (<a href="./references#CD010770-bbs2-0055" title="HigginsJPT , GreenS , editors. Cochrane handbook for systematic reviews of interventions. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). These tables evaluated the overall quality of the body of evidence for main review outcomes (symptom severity, health‐related quality of life, menstrual blood loss, rate of amenorrhoea, pelvic pain/pressure, SPRM‐associated endometrial changes) for main review comparisons (SPRM vs placebo and SPRM vs leuprolide acetate). We assessed the quality of the evidence using the following GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness and publication bias. Two review authors independently judged evidence quality (high, moderate, low or very low) and resolved disagreements by discussion. We justified, documented and incorporated these judgements into reporting of results for each outcome. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010770-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010770-sec-0053"></div> <section id="CD010770-sec-0054"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010770-sec-0154" title="">Characteristics of included studies</a> and <a href="./references#CD010770-sec-0155" title="">Characteristics of excluded studies</a>. </p> <section id="CD010770-sec-0055"> <h4 class="title">Results of the search</h4> <p>The electronic search of databases generated 476 records after we eliminated duplicates. We identified no additional records through handsearching and other sources. After screening titles and abstracts, we eliminated 437 records that did not meet review inclusion criteria. We retrieved 39 full‐text manuscripts and excluded 25 citations (15 were secondary publications/duplicated cohorts, 10 compared various doses of SPRM ‐ see <a href="./references#CD010770-sec-0155" title="">Characteristics of excluded studies</a>). We identified 10 ongoing trials (see <a href="./references#CD010770-sec-0157" title="">Characteristics of ongoing studies</a>) and included 14 studies in the review. <a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a> presented preliminary data on surgical outcomes after pretreatment with a variety of hormonal agents including ulipristal acetate. We could not extract data as no participants were treated with SPRM at the time of publication and investigators reported only surgery‐related outcomes. We did not include this study in further analyses in this review. Furthermore, we could not extract data from <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a> and <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>, as the numbers of participants assigned to treatment and control groups were unclear. Our attempts to contact study authors were unsuccessful. Hence, we used 11 studies for meta‐analysis. Two publications reported on the same participant cohort but reported different clinical outcomes; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a> reported these details. We have outlined details of the study screening process in <a href="#CD010770-fig-0001">Figure 1</a>. The search was current as of 15 May 2016. </p> </section> <section id="CD010770-sec-0056"> <h4 class="title">Included studies</h4> <p>For more information on included studies, see <a href="./references#CD010770-sec-0154" title="">Characteristics of included studies</a>. </p> <section id="CD010770-sec-0057"> <h5 class="title">Methods and setting</h5> <p>All studies were RCTs. Four studies were multi‐centre trials: three from European centres (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>) and one from a North American centre (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>). Four single‐site studies were conducted in the United States (<a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>); two in India (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>) and the remainder in Cuba (<a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>), China (<a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>), Sweden (<a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>) and Italy (<a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>). </p> </section> <section id="CD010770-sec-0058"> <h5 class="title">Participants</h5> <p>Studies included a total of 1215 study participants: 685 received SPRM and 336 were given a control. For two studies, numbers of participants in SPRM and control groups were unclear (<a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>). All studies, with one exception, included only patients with symptomatic fibroids. In <a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>, although participants were not expected to be symptomatic at baseline, most of them experienced symptoms (76% had abnormal uterine bleeding and 94% had bulk symptoms). Three studies scheduled participants for surgery for their symptomatic fibroids (<a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). Eight studies diagnosed uterine fibroids by ultrasonography, and three by MRI (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>). </p> <p>Eight studies reported the following ethnicities for 931 participants (91% of participants were included in this analysis): 644 White/Caucasian (69%), 183 Black (20%), 31 Asian (3%), 29 Afro‐Cuban (3%), 4 Hispanic (&lt; 1%) and 40 “other” (4%). </p> </section> <section id="CD010770-sec-0059"> <h5 class="title">Interventions</h5> <p>The SPRM in seven studies was mifepristone (see <a href="#CD010770-tbl-0003">Table 1</a>). Five studies investigated ulipristal acetate (see <a href="#CD010770-tbl-0004">Table 2</a>), and two investigated asoprisnil. <a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a> investigated three daily doses of asoprisnil (5 mg, 10 mg, 25 mg) and compared them with placebo over a three‐month period. <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a> compared 10 mg and 25 mg daily of asoprisnil versus placebo over three months in a cohort of 33 participants (see <a href="#CD010770-tbl-0005">Table 3</a>). </p> <div class="table" id="CD010770-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mifepristone studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leuprolide acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010770-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ulipristal acetate studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 or 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 or 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leuprolide acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 or 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 or 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010770-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Asoprisnil studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 or 10 or 25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 or 25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD010770-sec-0060"> <h5 class="title">Outcomes</h5> <p>All participant cohorts, with three exceptions (<a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>), reported on the primary outcome: fibroid‐related symptoms. Researchers assessed fibroid symptoms by measuring quality of life, menstrual bleeding and pelvic pain/pressure. </p> <p>Seven studies reported quality of life. Six studies used the Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL) (<a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). In addition to the UFS‐QoL, three studies (<a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>) reported quality of life using Short Form‐36. <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a> assessed quality of life by using a unique questionnaire on discomfort associated with uterine fibroids. </p> <p>Studies used both the symptom severity scale (SS‐QoL) and the Health‐Related Quality of Life scale (HR‐QoL) of the UFS‐QoL. Both measure aspects of fibroid‐related symptoms. They are mutually exclusive, and no overlap in scoring occurs between the two outcomes. The SS‐QoL (range 0 to 100) assesses bleeding, abdominal pressure, urinary frequency and fatigue. The HR‐QoL ranges from 0 to 100 points and is comprised of six domains: Concern, Activities, Energy/Mood, Control, Self‐Conscious and Sexual Function. </p> <p>With the exception of <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a> and <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>, all participant cohorts reported on the change in menstrual bleeding. At a minimum, investigators reported attainment of amenorrhoea at the end of the follow‐up period as a proportion. They frequently reported haemoglobin at baseline and at follow‐up. Four studies used standardised outcome measures to better quantify menstrual blood loss. Three studies (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>) used the pictorial blood loss assessment chart (PBAC) (<a href="./references#CD010770-bbs2-0056" title="HighamJM , O'BrienPMS , ShawRW . Assessment of menstrual blood loss using a pictorial chart. BJOG1990;97:734‐9. ">Higham 1990</a>). A PBAC score of 100 or higher correlates with menorrhagia, which is defined as menstrual blood loss greater than 80 mL (<a href="./references#CD010770-bbs2-0056" title="HighamJM , O'BrienPMS , ShawRW . Assessment of menstrual blood loss using a pictorial chart. BJOG1990;97:734‐9. ">Higham 1990</a>). <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a> used a visual analogue menstrual pictogram (<a href="./references#CD010770-bbs2-0077" title="WyattKM , DimmockPW , WalkerTJ , O’BrienPMS . Determination of total menstrual blood loss. Fertility and Sterility2001;76:125‐31. ">Wyatt 2001</a>), and how <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a> assessed menstrual blood loss remains unclear. </p> <p>Eight studies reported pelvic pain/pressure in a heterogeneous fashion. Outcome measures for pelvic pain included the McGill Pain Questionnaire, which has a score range of 0 to 45 (higher scores indicating greater pain) (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>), a visual analogue scale (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>), study‐specific Likert scales (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>) or a daily calendar log assessing the number of days pain was present (<a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>). Five studies reported changes in pelvic pressure symptoms following treatment using Likert scales (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>), a visual analogue scale (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>) or participant‐reported presence/absence of pressure symptoms (<a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>). </p> <p>Researchers assessed fibroid and uterine volume using ultrasonography in all patient cohorts, with the exception of <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>, which used serial MRI. Each study used different methods of calculation. See <a href="./references#CD010770-sec-0154" title="">Characteristics of included studies</a>. </p> <p>Studies, with the exception of <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>, reported endometrial histology for all participant cohorts. Studies differed in their criteria and timelines for performing endometrial biopsy and evaluated endometrial specimens using different pathological criteria. Four studies (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>) used the standard definition of SPRM‐associated endometrial changes (PAEC) provided by <a href="./references#CD010770-bbs2-0064" title="MutterGL , BergeronC , DeligdischL , FerenczyA , GlantM , MerinoM , et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology2008;21(5):591‐8. [PUBMED: 18246050] ">Mutter 2008</a>. Three studies (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>) evaluated specimens using their own semiquantitative assessment of glandular architecture as described in their respective manuscripts. Four studies (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>) evaluated endometrial histology but did not report on non‐physiological endometrial changes nor on PAEC. </p> </section> </section> <section id="CD010770-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Of 39 full‐text articles assessed, we excluded 25 studies for various reasons. Duplication of participant cohorts and studies that compared various doses of the same SPRM were the major reasons for exclusion. For more information on excluded studies, see <a href="./references#CD010770-sec-0155" title="">Characteristics of excluded studies</a>. </p> <section id="CD010770-sec-0062"> <h5 class="title">Ongoing studies</h5> <p>We identified 10 ongoing studies through searches of trials registers: seven ulipristal acetate, two vilaprisan and one telapristone acetate. See <a href="./references#CD010770-sec-0157" title="">Characteristics of ongoing studies</a>. From trial registers, we identified an additional 10 studies that had been completed or prematurely terminated. For details of these studies, see <a href="./references#CD010770-sec-0156" title="">Characteristics of studies awaiting classification</a>. We attempted to contact study authors to obtain data but were unsuccessful. </p> </section> </section> </section> <section id="CD010770-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010770-fig-0002">Figure 2</a> and <a href="#CD010770-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010770-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010770-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010770-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010770-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010770-sec-0064"> <h4 class="title">Allocation</h4> <p>Nine studies described true random sequence generation, and we graded them as having low risk (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). FIve studies provided insufficient details regarding the randomisation process; we therefore graded them as having unclear risk (<a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>). For concealment of allocation, we graded 10 studies as having low risk (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). Four studies provided no details of allocation concealment; we considered them as having unclear risk (<a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>). When risk of bias was unclear, we attempted to contact study authors to obtain clarification. </p> </section> <section id="CD010770-sec-0065"> <h4 class="title">Blinding</h4> <p>Ten studies described in detail adequate blinding of both study participants/personnel (performance bias) and outcome assessors (detection bias), and we graded them as having low risk (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). We considered the remaining four included studies as having unclear risk for both performance and detection bias owing to inadequate details on blinding (<a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>). </p> <p>We considered the same risk of bias criteria to be applicable to all outcomes.</p> </section> <section id="CD010770-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>We considered attrition bias to introduce low risk in nine included studies (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). We graded three studies as having unclear risk owing to insufficient details (<a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>). We considered only two studies as having high risk (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>). The Bagaria study included a disproportionate number of participants lost to follow‐up from placebo versus mifepristone groups (1/20 vs 4/20), and this was magnified by small study size. Similarly, the Esteve study reported unbalanced loss to follow‐up, with significantly more drop‐outs among placebo versus mifepristone groups (15/62 vs 4/62). </p> </section> <section id="CD010770-sec-0067"> <h4 class="title">Selective reporting</h4> <p>Eight studies were at low risk for reporting bias, with protocols available for each study and preselected outcome measures consistent with final reported outcomes in the published manuscripts (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). We graded five studies as having unclear risk (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>). For the Bagaria and Esteve studies, we identified no study protocol. The Bigatti, Liu and Prasad studies provided insufficient details of outcome measures, and we found no protocols for these studies. We attempted to contact study authors for clarification without success. We considered only one study to have high risk (<a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>) as we could not identify a protocol and, although investigators described fibroid volume in the methods section, they did not report this measure as an outcome. </p> </section> <section id="CD010770-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We identified four studies as having additional potential sources of bias (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>). In the Bagaria study, we noted potential for dose variation in the mifepristone group, as researchers provided no specific details regarding the capsule derivation method from 200 mg tablets and associated quality control. The Liu, Prasad and Bigatti studies were published as conference proceedings, and we graded them as having unclear risk owing to an overall lack of details. </p> </section> </section> <section id="CD010770-sec-0069"> <h3 class="title" id="CD010770-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD010770-tbl-0001"><b>Summary of findings for the main comparison</b> SPRM versus placebo</a>; <a href="./full#CD010770-tbl-0002"><b>Summary of findings 2</b> SPRM versus leuprolide acetate for uterine fibroids</a> </p> <section id="CD010770-sec-0070"> <h4 class="title">Comparison of SPRM versus placebo</h4> <p>Nine studies compared SPRM with placebo (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>) or vitamin B (<a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>). See <a href="./full#CD010770-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD010770-sec-0071"> <h5 class="title">PRIMARY OUTCOMES</h5> <section id="CD010770-sec-0072"> <h6 class="title">Fibroid‐related symptoms</h6> <section id="CD010770-sec-0073"> <p><b>Quality of life</b></p> <p>The UFS‐QoL is a validated measure of quality of life of patients with uterine fibroids (<a href="./references#CD010770-bbs2-0068" title="SpiesJB , CoyneK , Guaou GuaouN , BoyleD , Skyrnarz‐MurphyK , GonzalvesSM . The UFS‐QOL, a new disease‐specific symptom and health‐related quality of life questionnaire for leiomyomata. Obstetrics and Gynecology2002;99(2):290‐300. [PUBMED: 11814511] ">Spies 2002</a>). It consists of a symptom severity scale (SS‐QoL) and a health‐related quality of life scale (HR‐QoL). Subscales of the UFS‐QoL evaluate different domains of fibroid‐related symptoms and are mutually exclusive of each other; therefore, we meta‐analysed these separately. The SS‐QoL (range 0 to 100) assesses bleeding, abdominal pressure, urinary frequency and fatigue. A high symptom severity score means more severe fibroid symptoms. Investigators noted greater improvement in symptom severity scores in the SPRM group than in the placebo group, from baseline to end of treatment. Four studies that investigated mifepristone (<a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>), ulipristal acetate (<a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>) and asoprisnil (<a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>) demonstrated this over a three‐month treatment period. The mean difference in symptom severity score from baseline to end of treatment was ‐20.04 points (95% CI ‐26.63 to ‐13.46; 171 women, I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD010770-fig-0010" title="">Analysis 1.1</a>; <a href="#CD010770-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD010770-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.1 Change in symptom severity score (QoL)." data-id="CD010770-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.1 Change in symptom severity score (QoL). </p> </div> </div> </div> <p>The HR‐QoL subscale of the UFS‐QoL ranges from 0 to 100 points and comprises six domains: Concern, Activities, Energy/Mood, Control, Self‐Conscious and Sexual Function. A higher HR‐QoL score means better quality of life. Improvements in HR‐QoL were found during analysis of four studies investigating mifepristone (<a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>), ulipristal acetate (<a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>) and asoprisnil (<a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>). The treatment course was three months in all studies except <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>, which provided a six‐month treatment period. The mean difference in HR‐QoL scores from baseline to end of treatment was 22.52 points (95% CI 12.87 to 32.17; 200 women; I<sup>2</sup> = 63%; moderate‐quality evidence; <a href="./references#CD010770-fig-0011" title="">Analysis 1.2</a>; <a href="#CD010770-fig-0005">Figure 5</a>). This suggests greater improvement in HR‐QoL in the SPRM group than in the placebo group. Inclusion of few studies with each investigating different SPRMs may be contributing to heterogeneity. </p> <div class="figure" id="CD010770-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.2 Change in health‐related quality of life score." data-id="CD010770-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.2 Change in health‐related quality of life score. </p> </div> </div> </div> </section> <section id="CD010770-sec-0074"> <p><b>Abnormal uterine bleeding</b></p> <p>Relief of bleeding </p> <p>Fibroid‐related abnormal uterine bleeding symptoms were assessed in a heterogeneous fashion. We analysed various aspects separately: objective assessment of menstrual blood loss, proportion of amenorrhoeic participants at end of treatment and changes in haemoglobin (pretreatment and posttreatment). </p> <p>Menstrual blood loss </p> <p>Two studies investigating mifepristone (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>) and ulipristal acetate (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>) used the pictorial blood loss assessment chart (PBAC). A third study evaluating asoprisnil (<a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>) used a similar menstrual pictorial score. This tool had the same directionality as PBAC, in which higher scores translated to greater menstrual blood loss. Meta‐analysis of these studies revealed improvement in menstrual bleeding at the end of three months of SPRM treatment compared with placebo (SMD ‐1.11 points, 95% CI ‐1.38 to ‐0.83; 310 women, I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD010770-fig-0012" title="">Analysis 1.3</a>; <a href="#CD010770-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD010770-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.3 Change in menstrual blood loss." data-id="CD010770-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.3 Change in menstrual blood loss. </p> </div> </div> </div> <p>Amenorrhoea </p> <p>Seven studies investigating all three SPRMs consistently reported the proportion of participants who were amenorrhoeic at completion of treatment. Analysis demonstrates that participants treated with SPRMs for three to six months were more likely to be amenorrhoeic than those who received placebo (OR 82.50, 95% CI 37.10 to 183.90; 590 women, I<sup>2</sup> = 0%; moderate‐quality evidence; <a href="./references#CD010770-fig-0013" title="">Analysis 1.4</a>). However, the definition of amenorrhoea was not standard between studies. A range of definitions of amenorrhoea included the following: no bleeding/spotting for the entire study period (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>), six or fewer days of spotting (<a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>), PBAC score of 2 or less during weeks 9 to 12 (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>), cessation of menstruation (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>) and not specifically defined (<a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>). </p> <p>Haemoglobin </p> <p>We could not meta‐analyse change in haemoglobin levels from baseline to end of treatment to yield meaningful conclusions for the following reasons: inconsistent reporting of values (means, medians, percentage point change, P value only, etc.), missing data such as measures of spread and some groups taking iron with study drug. </p> <p>Eight studies reported on haemoglobin. Seven studies demonstrated an increase in haemoglobin at follow‐up in the SPRM group compared with the placebo group (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>). In <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>, haemoglobin levels were unchanged over the study period in placebo and SPRM groups. </p> </section> <section id="CD010770-sec-0075"> <p><b>Pain and pelvic pressure</b></p> <p>Investigators reported pelvic pain in a heterogenous manner, precluding meta‐analysis. Two studies (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>) used the McGill Pain Questionnaire (MPQ), two studies (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>) used a visual analogue scale (VAS) and the remaining studies used their own unique Likert scales (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>). </p> <p>Change in pain scores on the MPQ was less at completion of treatment compared with baseline only for the 10 mg ulipristal acetate dose compared with placebo (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>). <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a> reported a decrease in MPQ pain scores after treatment with 5 mg mifepristone, but this finding was not statistically significant. </p> <p><a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a> reported a non‐significant decrease in the proportion of participants experiencing complete resolution of pelvic pain, as measured by VAS, after treatment with 10 mg mifepristone. <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a> also used VAS and reported that participants treated with 5 mg mifepristone were more likely to be free of pelvic pain after completion of treatment. </p> <p>Of the three studies that used their own Likert scales to evaluate pelvic pain, two did not report improvement in symptoms (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>). <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a> presented data descriptively from daily participant journals, making it difficult for researchers to draw conclusions. </p> </section> </section> </section> <section id="CD010770-sec-0076"> <h5 class="title">SECONDARY OUTCOMES</h5> <section id="CD010770-sec-0077"> <h6 class="title">Change in fibroid or uterine size</h6> <section id="CD010770-sec-0078"> <p><b>Change in fibroid volume</b></p> <p>We reported data for this outcome per fibroid tracked rather than per woman randomised and have presented this information in <a href="#CD010770-tbl-0006">Table 4</a>. </p> <div class="table" id="CD010770-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Change in fibroid volume: SPRM versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SPRM type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>SPRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mifepristone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐41.5 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266.63 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mifepristone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.54 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mifepristone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐37.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours SPRM</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulipristal acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours SPRM</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulipristal acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours SPRM</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>cc: cubic centimetres</p> <p>MD: mean difference</p> <p>n: fibroids tracked</p> <p>SD: standard deviation</p> </div> </div> <p>Three mifepristone studies reported ‘mean difference’ in fibroid volume from baseline to end of treatment (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>). Two of these studies reported a decrease in fibroid volume among participants who received mifepristone compared with placebo/vitamin B. <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a> found that fibroids treated with mifepristone showed a decrease in volume compared with those treated with placebo. Two ulipristal acetate studies reported a ‘percent change’ in fibroid volume over the study period (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>). Both of these studies reported that participants treated with ulipristal acetate had a reduction in fibroid volume compared with those given placebo. Five additional studies (<a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a>; <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>) reported change in fibroid volume, but the quality of data prohibited data extraction and data were not analysed. However, qualitatively, these five studies reported a decrease in fibroid volume with SPRM treatment. </p> </section> <section id="CD010770-sec-0079"> <p><b>Change in uterine volume</b></p> <p>Three studies (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>) reported change in uterine volume after mifepristone treatment. Investigators reported a mean uterine volume reduction of 153.25 cc after treatment (MD ‐53.25 cc, 95% CI ‐262.19 to ‐44.32; 182 women). <a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a> also assessed uterine volume after ulipristal acetate therapy but reported data as ‘percent change’ in uterine volume. The treatment group had a non‐significant reduction in median uterine volume (5 mg dose, ‐12.1 percentage point change, 95% CI ‐28.3 to 2.9; 10 mg dose, ‐12.0 percentage point change, 95% CI ‐27.7 to 6.1) compared with the placebo group (5.9 percentage point change, 95% CI ‐3.8 to 18.4). Analysis of these four studies together revealed a reduction in uterine volume after SPRM treatment compared with placebo (SMD ‐0.63, 95% CI ‐0.91 to ‐0.36; 419 women, I<sup>2</sup> = 0; <a href="./references#CD010770-fig-0014" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD010770-sec-0080"> <h6 class="title">SPRM‐related effects</h6> <section id="CD010770-sec-0081"> <p><b>Endometrial histology</b></p> <p>Six studies comparing all three SPRMs versus placebo (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>; <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a>) and vitamin B (<a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>) assessed endometrial histology. Pathology criteria for evaluation of endometrial specimens differed between studies. Three studies (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a>) used the standard definition of SPRM‐associated endometrial changes (PAEC) provided by <a href="./references#CD010770-bbs2-0064" title="MutterGL , BergeronC , DeligdischL , FerenczyA , GlantM , MerinoM , et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology2008;21(5):591‐8. [PUBMED: 18246050] ">Mutter 2008</a>. <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a> and <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a> evaluated specimens using their own semiquantitative assessment of glandular architecture as described in their respective manuscripts. Meta‐analysis of five studies revealed that PAEC was more common after SPRM therapy than after placebo (OR 15.12, 95% CI 6.45 to 35.47; 405 women, I<sup>2</sup> = 0%; low‐quality evidence; <a href="./references#CD010770-fig-0015" title="">Analysis 1.6</a>). These six studies reported three cases of endometrial hyperplasia, all of which occurred in the SPRM treatment group (3/488). </p> <p><a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a> used a different approach to evaluate endometrial histology after asoprisnil treatment. Investigators developed a new classification system for endometrial biopsies that included two additional subcategories: non‐physiological secretory effect and secretory pattern mixed‐type. Among participants for which biopsies were available, 60/85 in the asoprisnil group were classified in these new histological categories compared with 4/30 participants in the placebo group. </p> <p>Four studies evaluated endometrial histology but did not report on non‐physiological endometrial changes or PAEC. <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a> included no participants with hyperplasia in the study group. <a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a> reported one case of hyperplasia in the ulipristal acetate group (1/12). <a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a> included 12/19 participants in the mifepristone group showing endometrial hyperplasia compared with none in the placebo group. The pathology definition used to classify endometrial hyperplasia in this study was not clearly specified nor was any mention made of a PAEC category. <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a> reported eight cases (25%) of 'cystic glandular hyperplasia' in the mifepristone group but provided unclear pathology criteria and an unclear rate of abnormal pathology in the placebo group. </p> </section> </section> </section> </section> <section id="CD010770-sec-0082"> <h4 class="title">Comparison of SPRMs versus alternative active therapy</h4> <p>Two studies compared SPRMs versus medical therapy (leuprolide acetate). No studies compared SPRMs versus surgical management or UAE. </p> </section> <section id="CD010770-sec-0083"> <h4 class="title">SPRM versus medical therapy: leuprolide acetate</h4> <p>See <a href="./full#CD010770-tbl-0002">summary of findings Table 2</a>. </p> <p>We included two studies for this comparison. <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a> evaluated 25 mg of mifepristone for three months, and we could extract only data for the uterine volume outcome. <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> evaluated 5 mg and 10 mg of ulipristal acetate for three months and reported on other patient‐reported outcomes, in addition to uterine volume. </p> <section id="CD010770-sec-0084"> <h5 class="title">PRIMARY OUTCOMES</h5> <section id="CD010770-sec-0085"> <h6 class="title">Fibroid‐related symptoms</h6> <section id="CD010770-sec-0086"> <p><b>Quality of life</b></p> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> found probably little or no difference in improvements in symptom severity score and HR‐QoL between ulipristal acetate and leuprolide groups using the UFS‐QoL. Results show no clear evidence of a difference in symptom severity score between SPRM and leuprolide groups (MD ‐3.70 points, 95% CI ‐9.85 to 2.45; 281 women; moderate‐quality evidence; <a href="./references#CD010770-fig-0016" title="">Analysis 2.1;</a><a href="#CD010770-fig-0007">Figure 7</a>), and probably little or no difference in HR‐QoL between SPRM and leuprolide groups (MD 1.06 points, 95% CI ‐5.73 to 7.85; 281 women; moderate‐quality evidence; <a href="./references#CD010770-fig-0017" title="">Analysis 2.2;</a><a href="#CD010770-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD010770-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.1 Change in symptom severity score (QoL)." data-id="CD010770-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.1 Change in symptom severity score (QoL). </p> </div> </div> </div> <div class="figure" id="CD010770-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.2 Change in health‐related quality of life score." data-id="CD010770-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.2 Change in health‐related quality of life score. </p> </div> </div> </div> </section> <section id="CD010770-sec-0087"> <p><b>Abnormal uterine bleeding</b></p> <p>Menstrual blood loss </p> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> found little or no difference in bleeding scores on the PBAC between ulipristal acetate and leuprolide (mean difference 6 percentage point change, 95% CI ‐40.95 to 50.95; 281 women; low‐quality evidence; <a href="./references#CD010770-fig-0018" title="">Analysis 2.3;</a><a href="#CD010770-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD010770-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.3 Change in menstrual blood loss." data-id="CD010770-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.3 Change in menstrual blood loss. </p> </div> </div> </div> <p>Amenorrhoea </p> <p>Results showed probably little or no difference between groups in rates of amenorrhoea (5 mg dose vs leuprolide: ‐5.2 percentage point change difference, 95% CI ‐18.7 to 8.6; 10 mg dose vs leuprolide: 9.0 percentage point change difference, 95% CI ‐2.8 to 21.0). Overall, the odds ratio for amenorrhoea for the SPRM group compared with the leuprolide group was 1.14 (95% CI 0.60 to 2.16; 280 women; moderate‐quality evidence; <a href="./references#CD010770-fig-0019" title="">Analysis 2.4</a>). </p> <p>Haemoglobin </p> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> found probably no difference in haemoglobin between groups (5 mg dose vs leuprolide: ‐0.02 percentage point change difference, 95% CI ‐0.3 to 0.3; 10 mg dose vs leuprolide: 0.03 percentage point change difference 95% CI ‐0.3 to 0.3). </p> </section> <section id="CD010770-sec-0088"> <p><b>Pain and pelvic pressure</b></p> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> used the McGill Pain Questionnaire and found clinically significant improvements in pelvic pain in all treatment groups. Pooled data showed probably little or no difference in improvement in pain scores between SPRM and leuprolide groups (MD ‐0.01 points on a 0 to 45 scale, 95% CI ‐2.14 to 2.12; 281 women; moderate‐quality evidence; <a href="./references#CD010770-fig-0020" title="">Analysis 2.5</a>). </p> </section> </section> </section> <section id="CD010770-sec-0089"> <h5 class="title">SECONDARY OUTCOMES</h5> <section id="CD010770-sec-0090"> <h6 class="title">Change in fibroid or uterine size</h6> <section id="CD010770-sec-0091"> <p><b>Change in fibroid size</b></p> <p>We reported data for this outcome per fibroid tracked rather than per woman randomised. We have provided this information in <a href="#CD010770-tbl-0007">Table 5</a>. </p> <div class="table" id="CD010770-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change in fibroid volume (%): SPRM versus leuprolide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>SPRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Leuprolide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Donnez 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐39.03%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐53.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours leuprolide</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MD: mean difference</p> <p>n: fibroids tracked</p> <p>SD: standard deviation</p> </div> </div> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> evaluated change in total volume of the three largest myomas. Participants treated with leuprolide showed a greater reduction in fibroid volume than those treated with ulipristal acetate. The median fibroid volume reduction at end of treatment was 36 percentage point change in the 5 mg group, 42 percentage point change in the 10 mg group and 53 percentage point change in the leuprolide group. When we pooled data for the 5 mg and 10 mg doses, we found that the leuprolide group (93 participants) showed greater shrinkage in fibroid volume than the SPRM group (188 participants). </p> </section> <section id="CD010770-sec-0092"> <p><b>Change in uterine size</b></p> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> and <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a> reported the percent change in uterine volume. Leuprolide was associated with decreased uterine volume at completion of treatment compared with SPRM. The reduction in uterine volume was 26% greater in the leuprolide group than in the SPRM group (MD 25.94%, 95% CI 20.49 to 31.39; 295 women, I<sup>2</sup> = 0%; <a href="./references#CD010770-fig-0021" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD010770-sec-0093"> <h6 class="title">SPRM‐related effects</h6> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> reported assessment of endometrial histology. This study used the definition of PAEC provided by <a href="./references#CD010770-bbs2-0064" title="MutterGL , BergeronC , DeligdischL , FerenczyA , GlantM , MerinoM , et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology2008;21(5):591‐8. [PUBMED: 18246050] ">Mutter 2008</a> and reported that PAEC was more common after SPRM therapy than after leuprolide treatment (OR 10.45, 95% CI 5.38 to 20.33; 301 women; moderate‐quality evidence; <a href="./references#CD010770-fig-0022" title="">Analysis 2.7</a>). </p> </section> </section> </section> <section id="CD010770-sec-0094"> <h4 class="title">Other analyses</h4> <section id="CD010770-sec-0095"> <h5 class="title">Formal assessment of reporting bias</h5> <p>We identified too few studies to construct a funnel plot to investigate publication bias. </p> </section> <section id="CD010770-sec-0096"> <h5 class="title">Subgroup analyses</h5> <p>Included studies were few and did not allow meaningful subgroup analyses with sufficient power. </p> </section> <section id="CD010770-sec-0097"> <h5 class="title">Sensitivity analyses</h5> <p>We applied a fixed‐effect model to our comparisons and found no significant changes in findings. When ORs were reported, we performed sensitivity analysis using risk ratio and encountered no changes to our results. Owing to the limited number of studies for primary outcomes, other planned sensitivity analyses were not possible. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010770-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010770-sec-0098"></div> <section id="CD010770-sec-0099"> <h3 class="title" id="CD010770-sec-0099">Summary of main results</h3> <p>This review included 14 randomised controlled trials (RCTs) that evaluated three types of selective progesterone receptor modulators (SPRMs; mifepristone, ulipristal acetate, asoprisnil). Moderate‐quality evidence shows that compared with placebo, SPRMs may improve quality of life, decrease menstrual blood loss and induce amenorrhoea. Trial results support treatment of individuals with uterine fibroids with SPRMs to improve fibroid‐related symptoms. Only two studies provided evidence obtained by comparing SPRMs versus a gonadotropin‐releasing agonist (GnRHa), and only one of these studies used sound study methods (<a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>). These limited data of moderate quality show probably little or no difference between leuprolide and SPRM in improving quality of life, achieving amenorrhoea and improving pelvic pain. Data from only one study provided insufficient evidence to allow a recommendation regarding the efficacy of one class of drugs over another for treatment of individuals with fibroid‐related symptoms. </p> <p>Investigators evaluated quality of life by using two components of the Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL): symptom severity (SS‐QoL) and health‐related quality of life (HR‐QoL). Moderate‐quality evidence for both quality of life outcomes showed probable improvement with SPRM treatment compared with placebo. </p> <p>Moderate‐quality evidence shows that SPRMs are probably effective in achieving amenorrhoea. The odds of achieving amenorrhoea with SPRM treatment were calculated at 82.50 compared with placebo (or 29 per 1000 in the placebo group vs 477 per 1000 in the SPRM group). See <a href="./full#CD010770-tbl-0001">summary of findings Table for the main comparison</a>. Furthermore, moderate‐quality evidence showed that menstrual blood loss is probably reduced with SPRM treatment. Measurement of menstrual blood loss differed between studies. Four studies used pictorial blood loss assessment charts, and the others used daily diaries, numerical rating scores or composite scores extracted from the UFS‐QoL. No studies used the alkaline‐hematin method ‐ a well‐validated quantitative assessment of menstrual bleeding. </p> <p>There remains a relative paucity of data on comparison of SPRMs against other medical management options for fibroids. One RCT (<a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>) reported probably little or no difference between SPRM and leuprolide with respect to improved quality of life and menstrual bleeding scores. This same study showed that leuprolide was more effective than SPRMs in reducing fibroid volume (<a href="./references#CD010770-fig-0021" title="">Analysis 2.6</a>). Similarly, two RCTs showed that leuprolide was more effective than SPRM in reducing uterine volume (<a href="./references#CD010770-fig-0021" title="">Analysis 2.6</a>). This discrepancy between differential change in uterine/fibroid volume and similar improvements in bleeding symptoms suggests that SPRM mechanisms underpinning control of bleeding may be independent of fibroid shrinkage; this interaction is poorly understood (<a href="./references#CD010770-bbs2-0073" title="WagenfeldA , SaundersPT , WhitakerL , CritchleyHO . Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opinion on Therapeutic Targets2016;20(9):1‐10. [PUBMED: 27138351] ">Wagenfeld 2016</a>). </p> <p>In keeping with known effects of SPRMs, low‐quality evidence suggests increased risk of selective progesterone receptor modulator‐associated endometrial changes (PAEC) in women treated with SPRMs versus placebo, and moderate‐quality evidence shows similar risk in comparisons with leuprolide. However, PAEC was not universally observed in all study participants (odds ratio (OR) 15.12, 95% confidence interval (CI) 4.65 to 35.47 in the comparison of SPRM vs placebo). Overall, endometrial hyperplasia was not increased after SPRM treatment. Increased rates of endometrial hyperplasia seen in one small study (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>) may be explained by misclassification of endometrial pathology. In light of published criteria for classifying SPRM endometrial effects (<a href="./references#CD010770-bbs2-0064" title="MutterGL , BergeronC , DeligdischL , FerenczyA , GlantM , MerinoM , et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology2008;21(5):591‐8. [PUBMED: 18246050] ">Mutter 2008)</a>, this study made no mention of a PAEC category and could have misclassified PAEC for hyperplasia. </p> </section> <section id="CD010770-sec-0100"> <h3 class="title" id="CD010770-sec-0100">Overall completeness and applicability of evidence</h3> <p>This review sought to assess the efficacy and safety of SPRMs. Researchers have reported improvements in key outcome measures when comparing SPRMs with placebo. However, additional studies comparing SPRMs versus other treatments for fibroids are needed. At present, an RCT fitting our inclusion criteria identified only leuprolide as a comparator. Other clinical trials evaluating SPRMs have not yet published results in peer‐reviewed journals nor on clinicaltrials.gov. Failure of investigators and industry to publish results of RCTs promptly has made our review vulnerable to publication bias. </p> <p>With regard to safety outcomes, study authors have reported no increase in endometrial hyperplasia/malignancy after SPRM treatment. One study demonstrated an increase in endometrial hyperplasia (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>), but this study had serious limitations, as was previously discussed. Safety and efficacy data from this review are valid only for a treatment course of three months, as most included trials were of 12 weeks duration. The exception was <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>, in which participants were treated for six months with no reports of hyperplasia in either group. Since the time of publication of these RCTs, more data have become available regarding endometrial safety and sustained efficacy over longer treatment periods (<a href="./references#CD010770-bbs2-0020" title="DonnezJ , VazquezF , TomaszewskiJ , NouriK , BouchardP , FauserBCJM , et al. Long‐term treatment of uterine fibroids with ulipristal acetate. Fertility and Sterility2014;101:1565‐73.e18. ">Donnez 2014</a>; <a href="./references#CD010770-bbs2-0052" title="DonnezJ , HudecekR , DonnezO , MatuleD , ArhendtHJ , ZatikJ , et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertility and Sterility2015;103(2):519‐27.e3. [PUBMED: 25542821] ">Donnez 2015</a>). </p> <p>Studies were conducted in Europe, North America, Cuba and India and included participants from diverse ethnic groups. However, it should be noted that participants from the PEARL (PGL4001 Efficacy Assessment in Reduction of Symptoms due to Uterine Leiomyomata) studies (<a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a>; <a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a>) represented a significant number of those included in this meta‐analysis (549/1021). Inclusion criteria for the PEARL studies required that women have high pictorial blood loss assessment chart (PBAC) scores, anaemia and myomata larger than 3 cm. Participants were predominantly White Eastern European women. Thus, the results of this review may not be fully applicable to women with smaller, less symptomatic myomata or to those from other ethnic groups. Some evidence suggests that ulipristal acetate (UPA) may result in variable outcomes according to ethnicity (<a href="./references#CD010770-bbs2-0063" title="MurjiA , CrosierR , ChowT , YeXY , ShirreffL . Role of ethnicity in treating uterine fibroids with ulipristal acetate. Fertility and Sterility2016;106(5):1165‐9. [PUBMED: 27336213] ">Murji 2016</a>). </p> </section> <section id="CD010770-sec-0101"> <h3 class="title" id="CD010770-sec-0101">Quality of the evidence</h3> <p>More than half (8/14) of the included studies were at low risk of bias in all domains. The most common limitation in other studies was poor reporting of methods. We graded four studies in particular as having unclear risk across most domains primarily owing to insufficient detail in their description of study methods (<a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a>; <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a>; <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>). The Bigatti, Liu and Prasad papers were conference proceedings from which we could not extract reliable data, and we did not include these studies in the meta‐analyses. </p> <p>Comparison of SPRM versus placebo yielded moderate‐quality evidence for most primary outcomes. We downgraded all evidence at least one level owing to strong suspicion of publication bias. Most of these studies included a small number of participants with positive results. We included no large negative studies in this review. Many unpublished industry‐sponsored studies further raise our concern regarding publication bias. Assessment of risk of SPRM‐associated endometrial changes yielded low‐quality evidence mainly owing to serious risk of measurement bias (due to inconsistencies in evaluation of endometrial histology). </p> <p>Comparison of SPRM versus leuprolide generated mostly evidence of moderate quality. Again, we consistently downgraded the quality by one level owing to publication bias. For the outcome of change in menstrual blood loss, low‐quality evidence was due to very serious issues with imprecision. </p> <p>One of the challenges for authors of this review was variable reporting of outcomes in these studies, particularly with regard to methods of assessing menstrual blood loss, fibroid/uterine size and quality of life parameters. Future trials assessing impact on fibroid size via imaging may wish to consider stereological assessment of the uterus rather than use of standard calliper methods (<a href="./references#CD010770-bbs2-0070" title="ThrippletonMJ , MunroKI , McKillopG , NewbyDE , MarshallI , RobertsN , et al. Unbiased and efficient estimation of the volume of the fibroid uterus using the Cavalieri method and magnetic resonance imaging. Reproductive Sciences2015;22(1):15‐22. [PUBMED: 25332217] ">Thrippleton 2015</a>). Consensus decisions regarding core reporting outcomes will facilitate future reviews and will permit greater ease of comparison in both future meta‐analyses and network analysis (<a href="./references#CD010770-bbs2-0060" title="KhanK . The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health. BJOG2014; Vol. 121, issue 10:1181‐2. [PUBMED: 24889142] ">Khan 2014</a>; http://www.crown‐initiative.org). </p> </section> <section id="CD010770-sec-0102"> <h3 class="title" id="CD010770-sec-0102">Potential biases in the review process</h3> <p>Our literature search was comprehensive; in addition to conducting database searches, we handsearched appropriate journals, clinical trial databases and conference proceedings. Other SPRMs for which results have not yet been published are undergoing evaluation. Seven of ten studies awaiting classification were investigating telapristone acetate. Although these phase 2 and 3 studies have been completed, results are not yet published. Each of asoprisnil, vilaprisan or ulipristal acetate was the topic of one study with unpublished results. </p> <p>Review authors made all important decisions regarding inclusion, bias and other aspects of analysis by discussion and consensus. When necessary, we sought additional evidence from trial authors that would help us accurately determine risk of bias. The main risk of bias involves the quality of some studies, small sample sizes and variable reporting of outcomes. </p> </section> <section id="CD010770-sec-0103"> <h3 class="title" id="CD010770-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>A previously published Cochrane review examined the use of mifepristone for uterine fibroids (<a href="./references#CD010770-bbs2-0071" title="TristanM , OrozcoLJ , SteedA , Ramirez‐MoreraA , StoneP . Mifepristone for uterine fibroids. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD007687.pub2] ">Tristan 2012</a>). Our review includes two additional studies investigating mifepristone (<a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a>; <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a>). Data from <a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a> were published subsequent to the <a href="./references#CD010770-bbs2-0071" title="TristanM , OrozcoLJ , SteedA , Ramirez‐MoreraA , StoneP . Mifepristone for uterine fibroids. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD007687.pub2] ">Tristan 2012</a> review. In the spirit of inclusiveness, we decided to include <a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a> data in our meta‐analysis but discussed its methodological issues both in the text and in risk of bias tables. However, owing to the small number of participants, the Reinsch study did not have a significant impact on the overall magnitude of effect size. </p> <p>We also included in our analysis the three studies that were included in the <a href="./references#CD010770-bbs2-0071" title="TristanM , OrozcoLJ , SteedA , Ramirez‐MoreraA , StoneP . Mifepristone for uterine fibroids. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD007687.pub2] ">Tristan 2012</a> mifepristone review (<a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a>; <a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a>; <a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a>). Some minor differences in risk of bias assessments are evident. All review authors re‐evaluated these discrepancies and assigned final bias ratings by consensus in a manner that was consistent with ratings for other studies included in our review. Our findings are consistent with and extend those presented in the <a href="./references#CD010770-bbs2-0071" title="TristanM , OrozcoLJ , SteedA , Ramirez‐MoreraA , StoneP . Mifepristone for uterine fibroids. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD007687.pub2] ">Tristan 2012</a> review. As a result of the larger number of participants in our study (1021 vs 112), we were able to demonstrate that SPRMs reduce fibroid volume and improve fibroid‐specific quality of life. Our review confirmed the finding that SPRMs reduce heavy menstrual bleeding. </p> <p>Another Cochrane review investigated the role of pretreatment with GnRH analogues before a major surgical procedure ‐ hysterectomy or myomectomy ‐ for uterine fibroids (<a href="./references#CD010770-bbs2-0061" title="LethabyA , VollenhovenB , SowterMC . Pre‐operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD000547] ">Lethaby 2001</a>). An update of this review with an expanded scope including all medical therapies used before surgery for fibroids is under editorial review. </p> <p>Our findings also build upon the results of other systematic reviews. For example, a meta‐analysis of ulipristal acetate for treatment of uterine fibroids found that this drug was associated with improved quality of life and reduced fibroid size when compared with placebo (<a href="./references#CD010770-bbs2-0058" title="KalampokasT , KamathM , BoutasI , KalampokasE . Ulipristal acetate for uterine fibroids: a systematic review and meta‐analysis. Gynecological Endocrinology2016;32(2):91‐6. [PUBMED: 26572056] ">Kalampokas 2016</a>). This meta‐analysis was based on the same four ulipristal acetate studies included in our review. </p> <p>Another systematic review of medical treatments for fibroids included 75 RCTs, 47 of which contributed to the network meta‐analysis (<a href="./references#CD010770-bbs2-0054" title="GurusamyKS , VaughanJ , FraserIS , BestLM , RichardsT . Medical therapies for uterine fibroids ‐ a systematic review and network meta‐analysis of randomised controlled trials. PloS one2016;11(2):e0149631. [PUBMED: 26919185] ">Gurusamy 2016</a>). This meta‐analysis included the same 11 studies as were included in our review. We included three additional studies as well: <a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a> (Williams 2007 publication) reported on outcome measures of interest in our protocol, and <a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a> and <a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a> were published subsequent to the <a href="./references#CD010770-bbs2-0054" title="GurusamyKS , VaughanJ , FraserIS , BestLM , RichardsT . Medical therapies for uterine fibroids ‐ a systematic review and network meta‐analysis of randomised controlled trials. PloS one2016;11(2):e0149631. [PUBMED: 26919185] ">Gurusamy 2016</a> review. The <a href="./references#CD010770-bbs2-0054" title="GurusamyKS , VaughanJ , FraserIS , BestLM , RichardsT . Medical therapies for uterine fibroids ‐ a systematic review and network meta‐analysis of randomised controlled trials. PloS one2016;11(2):e0149631. [PUBMED: 26919185] ">Gurusamy 2016</a> review rated risk of study bias as higher than we did, possibly because we solicited additional information/protocols from study authors that allowed us to downgrade some risk of bias assessments. The biggest difference between the two reviews involved the outcomes chosen for comparison. Our review focused on analysis of outcomes that directly impact and are clinically meaningful to patients. Our primary outcomes were changes in fibroid‐related symptoms (quality of life, amenorrhoea, reduction in bleeding, etc.). The Gurusamy review reported on the proportion of patients treated medically who underwent surgery, as well as haemoglobin levels and adverse events. On the basis of these limited comparisons, review authors concluded that evidence was insufficient to recommend medical treatment for patients with fibroids. On the basis of outcomes that we evaluated, we arrived at a different conclusion. We found that moderate‐quality evidence showed that SPRMs are more effective in improving patient‐reported outcomes when compared with placebo. </p> <p>Several ongoing clinical trials are examining different drugs in the class of SPRMs. Results from these trials may alter subsequent updates of this review. Many of these ongoing trials are comparing SPRMs with other drugs rather than with placebo. These results will be of particular interest, as they will add to the literature and perhaps will inform clinical decision making. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010770-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010770-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010770-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010770-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.1 Change in symptom severity score (QoL)." data-id="CD010770-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.1 Change in symptom severity score (QoL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.2 Change in health‐related quality of life score." data-id="CD010770-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.2 Change in health‐related quality of life score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.3 Change in menstrual blood loss." data-id="CD010770-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 SPRM versus placebo, outcome: 1.3 Change in menstrual blood loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.1 Change in symptom severity score (QoL)." data-id="CD010770-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.1 Change in symptom severity score (QoL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.2 Change in health‐related quality of life score." data-id="CD010770-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.2 Change in health‐related quality of life score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.3 Change in menstrual blood loss." data-id="CD010770-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 SPRM versus leuprolide acetate, outcome: 2.3 Change in menstrual blood loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SPRM versus placebo, Outcome 1 Change in symptom severity score (QoL)." data-id="CD010770-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 SPRM versus placebo, Outcome 1 Change in symptom severity score (QoL).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SPRM versus placebo, Outcome 2 Change in health‐related quality of life score." data-id="CD010770-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 SPRM versus placebo, Outcome 2 Change in health‐related quality of life score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SPRM versus placebo, Outcome 3 Change in menstrual blood loss." data-id="CD010770-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 SPRM versus placebo, Outcome 3 Change in menstrual blood loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SPRM versus placebo, Outcome 4 Amenorrhoea." data-id="CD010770-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 SPRM versus placebo, Outcome 4 Amenorrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SPRM versus placebo, Outcome 5 Change in uterine volume." data-id="CD010770-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 SPRM versus placebo, Outcome 5 Change in uterine volume.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SPRM versus placebo, Outcome 6 SPRM‐associated endometrial changes." data-id="CD010770-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 SPRM versus placebo, Outcome 6 SPRM‐associated endometrial changes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 SPRM versus leuprolide acetate, Outcome 1 Change in symptom severity score (QoL)." data-id="CD010770-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 SPRM versus leuprolide acetate, Outcome 1 Change in symptom severity score (QoL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 SPRM versus leuprolide acetate, Outcome 2 Change in health‐related quality of life score." data-id="CD010770-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 SPRM versus leuprolide acetate, Outcome 2 Change in health‐related quality of life score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-002-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 SPRM versus leuprolide acetate, Outcome 3 Change in menstrual blood loss." data-id="CD010770-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 SPRM versus leuprolide acetate, Outcome 3 Change in menstrual blood loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 SPRM versus leuprolide acetate, Outcome 4 Amenorrhoea." data-id="CD010770-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 SPRM versus leuprolide acetate, Outcome 4 Amenorrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 SPRM versus leuprolide acetate, Outcome 5 Change in pelvic pain." data-id="CD010770-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 SPRM versus leuprolide acetate, Outcome 5 Change in pelvic pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 SPRM versus leuprolide acetate, Outcome 6 Percent change in uterine volume." data-id="CD010770-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 SPRM versus leuprolide acetate, Outcome 6 Percent change in uterine volume.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010770-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/urn:x-wiley:14651858:media:CD010770:CD010770-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_t/tCD010770-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 SPRM versus leuprolide acetate, Outcome 7 SPRM‐associated endometrial changes." data-id="CD010770-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 SPRM versus leuprolide acetate, Outcome 7 SPRM‐associated endometrial changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/media/CDSR/CD010770/image_n/nCD010770-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010770-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">SPRM versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>SPRM vs placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with uterine fibroids<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> SPRM<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SPRM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in symptom severity score measured with Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL): scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in symptom severity score (QoL) in the intervention group was 20.04 points lower (26.63 lower to 13.46 lower), indicating improvement in symptom severity with SPRM treatment for 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in health‐related quality of life score measured with UFS‐QoL: scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in health‐related quality of life score in the intervention group was 22.52 points higher (12.87 higher to 32.17 higher), indicating improvement in quality of life with SPRM treatment for 3 to 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 RCT (Fiscella 2006) reported outcomes at 6 months. Remaining studies had a 3‐month follow‐up period </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> change in menstrual blood loss </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in menstrual blood loss in the intervention group was 1.11 points lower (1.38 lower to 0.83 lower), indicating a decrease in menstrual blood loss with SPRM treatment for 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measured by PBAC score or similar menstrual pictorial score. PBAC score ≥ 100 correlates with menorrhagia, which is defined as &gt; 80 mL menstrual blood loss </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> amenorrhoea </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>477 per 1000<br/> (237 to 961) with 3 to 6 months of SPRM treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 82.50<br/> (37.10 to 183.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 RCT (Fiscella 2006) reported outcomes at 6 months. Remaining studies had a 3‐month follow‐up period </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pelvic pain</b> (measured subjectively) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No conclusions could be drawn owing to variability in estimates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>629</p> <p>(7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> SPRM‐associated endometrial changes </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000<br/> (176 to 697) with 3 months of SPRM treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 15.12<br/> (6.45 to 35.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>405<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>Risk in the intervention group</b> (and its 95% confidence interval) is based on mean risk in the comparison group and <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as publication bias suspected because no small negative studies included. Also, many studies were conducted and not published </p> <p><sup>b</sup>Downgraded one level because of serious issues with indirectness of evidence when criteria for evaluating endometrial specimens differed between studies </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">SPRM versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010770-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">SPRM versus leuprolide acetate for uterine fibroids</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SPRM versus leuprolide acetate for uterine fibroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> uterine fibroids<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> SPRM<br/> <b>Comparison:</b> leuprolide acetate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with leuprolide acetate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SPRM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in symptom severity score measured with Uterine Fibroid Symptom Quality of Life Scale (UFS‐QoL): scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in symptom severity score (QoL) in the SPRM group was 3.7 points lower<br/> (9.85 lower to 2.45 higher) compared with the leuprolide group at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life:</b> change in health‐related quality of life score measured with UFS‐QoL: scale 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in health‐related quality of life score in the SPRM group was 1.06 points higher<br/> (5.73 lower to 7.85 higher) compared with the leuprolide group at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> change in menstrual blood loss (measured using PBAC score) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in menstrual blood loss in the SPRM group was 6 points higher<br/> (40.95 lower to 52.95 higher) compared with the leuprolide group at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PBAC score ≥ 100 correlates with menorrhagia, which is defined as &gt; 80 mL menstrual blood loss </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal uterine bleeding:</b> amenorrhoea </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>804 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>828 per 1000<br/> (732 to 933) at 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.14<br/> (0.60 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pelvic pain</b> (measured using McGill Pain Questionnaire: range 0 to 45) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean change in pelvic pain in the SPRM group was 0.01 points lower (2.14 lower to 2.12 higher) than in the leuprolide group at 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects:</b> SPRM‐associated endometrial changes </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>585 per 1000<br/> (340 to 1000) after 3 months of treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 10.45<br/> (5.38 to 20.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>Risk in the intervention group</b> (and its 95% confidence interval) is based on mean risk in the comparison group and <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; OR: odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level as publication bias strongly suspected </p> <p><sup>b</sup>Downgraded one level owing to serious issue with imprecision as point estimate has very wide confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">SPRM versus leuprolide acetate for uterine fibroids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010770-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mifepristone studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0008" title="EisingerSH , FiscellaK , MeldrumS , FengC , FisherS , GuzickDS . Effect of mifepristone on quality of life for women with symptomatic fibroids. Fertility and Sterility2006;86:S41‐2. FiscellaK , EisingerSH , MeldrumS , FengC , FisherSG , GuzickDS . Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and Gynecology2006;108:1381‐7. ">Fiscella 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0010" title="LiuC . Low‐dose mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. Journal of Minimally Invasive Gynecology2015;22(6):S91. ">Liu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0012" title="PrasadS , VarunN , KumarA . Effect of low dose mifepristone on uterine leiomyoma in reproductive age group. Fertility and Sterility2013;3:S78. ">Prasad 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0013" title="ReinschRC , MurphyAA , MoralesAJ , YenSS . The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American Journal of Obstetrics and Gynecology1994;170:1623‐7; discussion 1627‐8. ">Reinsch 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leuprolide acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mifepristone studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010770-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ulipristal acetate studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0002" title="BigattiG , LemmelloR , DesgroM , PollinoS , SantiroccoM . Progesterone preoperative treatment for myomectomy with the intrauterine bigatti shaver (IBS). Gynecological Surgery2014;1:119‐20. ">Bigatti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 or 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0005" title="DonnezJ , TomaszewskiJ , VazquezF , BouchardP , LemieszczukB , BaroF , et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine2012;366:421‐32. ">Donnez 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 or 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leuprolide acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010770-bbs2-0009" title="LevensED , Potlog‐NahariC , ArmstrongAY , WesleyR , PremkumarA , BlitheDL , et al. CDB‐2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and Gynecology2008;111:1129‐36. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Levens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 or 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 or 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ulipristal acetate studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010770-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Asoprisnil studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0003" title="ChwaliszK , LarsenL , EdmondsA , WinkelC . Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM) in treating uterine leiomyomata. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress. 2005. ChwaliszK , LarsenL , Mattia‐GoldbergC , EdmondsA , ElgerW , WinkelCA . A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and Sterility2007;87:1399‐412. ChwaliszK , LarsenL , McCraryK , EdmondsA . Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. Journal of the Society for Gynecologic Investigation2004;11:320A‐1A. LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences (Thousand Oaks, Calif.)2013;20:680‐7. ">Chwalisz 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 or 10 or 25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0014" title="LarsenL , CoyneK , ChwaliszK . Validation of the menstrual pictogram in women with leiomyomata associated with heavy menstrual bleeding. Reproductive Sciences2013;20:680‐7. WilkensJ , ChwaliszK , HanC , WalkerJ , CameronIT , IngamellsS , et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Journal of Clinical Endocrinology and Metabolism2008;93:4664‐71. WilkensJ , MaleV , GhazalP , ForsterT , GibsonDA , WilliamsAR , et al. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Journal of Immunology2013;191(5):2226‐35. WilkensJ , WilliamsAR , ChwaliszK , HanC , CameronIT , CritchleyHO . Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. Human Reproduction2009;24:1036‐44. WilliamsAR , CritchleyHO , OseiJ , IngamellsS , CameronIT , HanC , et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Human Reproduction2007;22:1696‐704. ">Wilkens 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 or 25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Asoprisnil studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010770-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Change in fibroid volume: SPRM versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SPRM type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>SPRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0001" title="BagariaM , SunejaA , VaidNB , GuleriaK , MishraK . Low‐dose mifepristone in treatment of uterine leiomyoma: a randomised double‐blind placebo‐controlled clinical trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2009;49:77‐83. ">Bagaria 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mifepristone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐41.5 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266.63 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0006" title="EngmanM , GranbergS , WilliamsAR , MengCX , LalitkumarPG , Gemzell‐DanielssonK . Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction2009;24:1870‐9. ">Engman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mifepristone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.54 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0007" title="EsteveJL , AcostaR , PerezY , RodriguezB , SeiglerI , SanchezC , et al. Mifepristone versus placebo to treat uterine myoma: a double‐blind, randomized clinical trial. International Journal of Womens Health2013;5:361‐9. ">Esteve 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mifepristone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐37.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.0 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1 cc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours SPRM</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0004" title="BarlowDH , LumsdenMA , FauserBCJM , TerrillP , BestelE . Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction2014;29:480‐9. DonnezJ , TatarchukTF , BouchardP , PuscasiuL , ZakharenkoNF , IvanovaT , et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine2012;366:409‐20. WilliamsAR , BergeronC , BarlowDH , FerenczyA . Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology2012;31:556‐69. ">Donnez 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulipristal acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours SPRM</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010770-bbs2-0011" title="CoxJ , MalikM , Britten‐WebbJ , PatelA , MalikS , SegarsJ , et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial. Reproductive Sciences2015;22:88A. FruKN , LevyG , WesleyR , NeimanL , VenkatesanA , ArmstrongA . Prolactin as a biomarker for tumor burden and response to UPA therapy in African American women with symptomatic leiomyoma. Reproductive Sciences2013;20:150A. GreenL J , LevyG , WesleyR , NiemanL , ArmstrongA . Efficacy of ulipristal acetate for the treatment of symptomatic uterine leiomyomas in African Americans. Fertility and Sterility2013;98:S96. LevyG , AvilaN , ArmstrongAY , NiemanL . Does the selective progesterone receptor modulator ulipristal normalize the uterine cavity in women with leiomyoma. Reproductive Sciences2011;1:95A. NiemanL , Chabbert‐BuffetN , BouchardP . Endocrine safety of ulipristal acetate, a selective progesterone receptor modulator (SPRM): results from two phase II randomised, placebo‐controlled studies. Endocrine Abstracts2010;22:P480. NiemanLK , BlockerW , NanselT , MahoneyS , ReynoldsJ , BlitheD , et al. Efficacy and tolerability of CDB‐2914 treatment for symptomatic uterine fibroids: a randomized, double‐blind, placebo‐controlled, phase IIb study. Fertility and Sterility2011;95:767‐72 e1‐2. SegalTR , ZarekSM , MumfordSL , PlowdenTC , NiemanLK , SegarsJH , et al. Radiographic and histopathologic endometrial characteristics of women undergoing treatment with ulipristal acetate (UPA). Fertility and Sterility2014;102:e286. ">Nieman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulipristal acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours SPRM</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>cc: cubic centimetres</p> <p>MD: mean difference</p> <p>n: fibroids tracked</p> <p>SD: standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Change in fibroid volume: SPRM versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010770-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change in fibroid volume (%): SPRM versus leuprolide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>SPRM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Leuprolide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Donnez 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐39.03%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐53.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Favours leuprolide</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>MD: mean difference</p> <p>n: fibroids tracked</p> <p>SD: standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Change in fibroid volume (%): SPRM versus leuprolide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/full#CD010770-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010770-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SPRM versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in symptom severity score (QoL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.04 [‐26.63, ‐13.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in health‐related quality of life score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.52 [12.87, 32.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in menstrual blood loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐1.38, ‐0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Amenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>82.50 [37.01, 183.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in uterine volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐0.91, ‐0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 SPRM‐associated endometrial changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.12 [6.45, 35.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SPRM versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010770-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">SPRM versus leuprolide acetate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in symptom severity score (QoL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐9.85, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in health‐related quality of life score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [‐5.73, 7.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in menstrual blood loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [‐40.95, 52.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Amenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.60, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in pelvic pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐2.14, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Percent change in uterine volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.94 [20.49, 31.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 SPRM‐associated endometrial changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.45 [5.38, 20.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">SPRM versus leuprolide acetate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010770.pub2/references#CD010770-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010770.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010770-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010770-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010770-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD010770-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010770\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010770\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010770\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010770\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010770\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010770.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010770.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010770.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010770.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010770.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724266495"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010770.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724266498"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010770.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e5e9f4973f409',t:'MTc0MDcyNDI2Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 